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1.1 The hallmarks of cancer  
“Nothing in cancer makes sense except in the light of evolution”[1]. With this 
controversial sentence, paraphrasing Dobzhansky’s famous dictum, Mel Greaves describes 
how the study of cancer in evolutionary terms has transformed our understanding over its 
complexity. As a matter of fact, cancer results from the unregulated proliferation of any 
kinds of cells in the body; as a result there are more than a hundred distinct types of cancer 
and for each many subtypes, implying a high degree of variability and complexity in 
behavior and treatment´s response [2]. Tumor growth in the host body, resembling 
Darwin´s model of evolution, is provoked by several progressive genetic and epigenetic 
mutations, which confer differential cellular advantages in terms of adaptive capabilities 
that progressively support the transformation from a normal cell to a malignant one. 
These alterations, which often include DNA mutations, but as well rearrangements, 
deletions, and amplifications, are largely neutral (called “passenger” mutations), whether 
some provide a selective growth advantage, and therefore are called “driver” mutations [3]. 
The driver mutations involve gain-of-function of proto-oncogenes, which turn into 
oncogenes, and loss-of-function of tumor suppressor genes [4]. These alterations can be 
inherited, caused by environmental factors such as physical (UV, ionizing radiations), 
chemicals (tobacco smoke, aflatoxins as food contaminant components) or biological 
carcinogens (virus, bacteria, and parasites), or occur as errors during natural cell´s division.  
The National Cancer Institute reports that the incidence of cancer generally 
increases tenfold between ages 45 and 54 years with a later tenfold increase between 55 to 
64 years. This trend reflects the multistep nature of cancer development as a result of the 
accumulation of several abnormalities over time [5]. The microevolution theory of cancer 
bases on the clonal evolution model of tumor proposed by Peter Nowell published in 
Science in 1976 [6], which in turn constitutes one of the bases of the “Hallmarks of Cancer” 
published by Hanahan and Weinberg in 2000 [7]. This review, which persists at the core of 




essential cellular changes, which support tumor transformation. These gained capabilities, 
which lately in 2011 the authors updated to eight, include: functional capabilities as 
sustaining proliferative signaling, evasion of growth-inhibitory signals, circumvention of 
cell apoptosis, limitless replicative potential, induction of angiogenesis and activation of 
tumor invasion, and metastasis. Additional enabling characteristics include genome 
instability and tumor-promoting inflammation (Figure 1).  
Figure 1: “The Hallmarks of cancer”. The eight shared capacities acquired by the most types of tumors 
during neoplastic transformation, as proposed by Hanahan and Weinberg [8].  
Hanahan and Weinberg successfully provided a simplified framework for 
describing and studying tumorigenesis by looking to its underlying principles. 
However, cancer is still recognized as being a highly complex and heterogeneous disease 
with a high degree of variability within individual tumors and within and between tumor 
types [9]. Its overall complexity has been challenging the researchers since the beginning 
of the 20th century and still today cancer is worldwide the second cause of death, with an 




1.2 The tumoral microenvironment (TME) 
Nowadays it is clear that carcinogenic cells are alone unable to progress toward 
tumor formation but must receive active support by cellular and non-cellular components 
of the tumor niche, which constitute the tumoral microenvironment (TME). 
The TME, which is constituted by stroma cells such as cancer associated fibroblasts 
(CAFs), endothelial cells (ECs), pericytes, leukocytes, immune cells, tumor associated 
macrophages and extracellular matrix (ECM). The stroma contributes to tumorigenesis by 
providing to cancer a permissive environment [11,12]. During tumor progression, tumor 
and stroma cells within the TME reciprocally communicate: cancer cells activate ECM cells 
by secreting signaling factors (growth factors, chemokines, and cytokines), in turn, TME 
cells feedback to the tumor sending growth-promoting factors, and additionally, activate 
extensive remodeling of ECM architecture, to favor cancer growth and spread.  
 The extracellular matrix (ECM) 
The extracellular matrix (ECM) constitutes the non-cellular component of the TME, 
composed by a heterogeneous and dynamic complex of water, minerals, and proteins, 
including collagens, proteoglycans, elastin, and cell-binding glycoproteins as the major 
components [13]. The function of the ECM is to provide both a physical and a biochemical 
support structure to the resident cells [14]. In contrast to the earlier concept, which would 
relate the ECM to a merely passive function, we know today that ECM plays an active role 
in regulating cell physiology and homeostasis, being actively involved in controlling 
intracellular communication, cells adhesion, proliferation, differentiation, and migration 
[15,16].  
Yet, cancer cells usurp the ECM to favor its own progression. In tumorigenic 
tissues, the ECM undergoes continuous structural remodeling, and its abnormal dynamics, 
resulting in increased stiffness, are reported as a hallmark of cancer [17,18]. 
During tumorigenesis, the deregulated composition and over-production of ECM 
components support the upregulation of many signaling pathways involved in tumor 




of ECM-modifying enzymes, which enable cell infiltration through the ECM, as required 
during metastatic processes.  
1.2.1.1 Heparan sulfate proteoglycans (HSPGs) and heparin 
Diverse proteoglycans are components of the ECM and consist of a “core protein”, 
where one or several sulfated glycosaminoglycan (GAG) side chains are covalently 
attached [19]. Proteoglycans are involved in the regulation of many relevant biological 
functions as well as several pathological processes, such as inflammation [20], 
angiogenesis [21], neurodegeneration [22], and cancer [23]. Notably, these functions are 
mainly regulated via the binding of proteins, bacteria, and viruses to distinct GAG 
sequences. The GAGs are unbranched highly sulfated polysaccharides consisting of several 
repeats of anionic disaccharide units. Depending on the different disaccharide units, the 
GAGs can be as well categorized into four main groups: hyaluronic acid, keratan sulfate, 
chondroitin/dermatan sulfate, and heparin/heparan sulfate (HS) [24].  
Heparin is probably the most famous GAG, mainly concerning its anticoagulant 
capacity. Heparin and heparan sulfate (HS) present highly related structures (Figure 2). 
Both carbohydrate polymers derive from the same bio-precursor, the N-acetylheparosan (-
GlcA-GlcNAc)n, and are composed by α-linked repetitions of disaccharide units 
comprising an amino sugar (D-glucosamine (D-GlcN) or N-acetyl-D-glucosamine (D-
GlcNAc) and an uronic acid (D-glucuronic acid (D -GlcA) or L-iduronic acid (L-IdoA) 
[25]. However, during their synthesis, they undergo epimerization and sulfation at 
differential positions (primarily on GlcN and IdoA) [26].  
Heparin has a more homogeneous structure and is mainly composed of regular 
trisulfated disaccharide units (IdoA2S and GlcNS6S), eventually interrupted by uronic acid 
residues or undersulfated hexosamines. The high degree of sulfation and content of 
carboxyl groups turns heparin to the highest negatively charged known biological molecule. 
HS are, in contrast, more heterogeneous and, as undergo diverse post-translational 
modifications to generate various HSPGs, are involved in differential biological functions 
[27]. Furthermore, HS are characterized by lower iduronic acid (IdoA) content, a greater 
portion of glucuronic acid (GlcA), and overall a reduced degree of sulfation. Although both 




kDa). Nevertheless, given the structural similarity and the reduced heterogeneity, heparin 
has been extensively used as an analogue of HS for functional studies [28].  
Figure 2: Heparin and HSPGs structure. Illustration of heparin and HS structure, their major and minor 
disaccharide repeats and binding interactions. Reprinted under the permission of Shifaza M. and Coombe D. 
R. [26].  
While the structures show similarities, the biosynthesis of the two molecules differs 
substantially. HS are virtually expressed by every cell and can be located at the cell surface 
(as syndecans and glypicans) or found as free diffusible proteoglycans in the basement 
membrane and ECM (agrin, perlecan, type XVIII collagen). Heparin is indeed primarily 
synthetized by mast cells and found in the connective tissues; here it is stored in the granules 
in complex with histamine and mast-cells proteases [29,30].  
1.2.1.2 Heparin/HS signaling in cancer  
Functionalities of HS and heparin differ as well. HS bind to at least 300 proteins, 
including growth factors, morphogens, cytokines, chemokines, enzymes, enzyme 
inhibitors, and ECM structural proteins [31]. Via binding to the growth factors, HS 




involved in several physiological and pathological processes, such as cancer. The binding 
to HS controls mainly ligands localization and availability via protecting the growth factors 
from degradation, establishing a gradient in the ECM, and acting as extracellular ligand 
storage. Besides, HS may function as a co-receptor, directly regulating the cellular 
signaling controlled by the growth factors. Some HS binding growth factors elicit 
mitogenic and pro-angiogenic functions as fibroblast growth factor (FGF) and heparin-
binding EGF-like growth factor (HBEGF), others promote tumor survival and metastasis, 
such as Hedgehog (Hh), whereas vascular endothelial growth factor (VEGF) has both, pro-
angiogenic and metastatic functions. A comprehensive list of HS binding growth factors 
and cytokines is given in Table 1.  
Table 1: HSPGs and their binding interactions. In bold are highlighted the growth factors with confirmed 
affinity to both HS and heparin. Table reprinted under permission of Knelson E. H. et al. [27]. The references 
can be found in the original work. 
The HS-binding proteins constitute the “heparin interactome”, as most of the 
proteins have been identified via heparin-affinity chromatography. Considerably, the 
majority of the proteins bind to HS mainly via electrostatic interaction mediated by their 
positively charged Arg/Lys residues. In addition, the basic sequence is often aligned in an 
evolutionary conserved motif as the “Cardin Weintraub” motif [CW: XBBBXXBX, where 
B are a basic Arg/Lys residues and X stands for hydropathic residues (Ala, Gly, Ile, Leu or 
Tyr)], discovered as a proteins consensus sequence for heparin recognition [32,33]. 
Nevertheless, the binding of HS/heparin to proteins depends as well on the binding to 
Receptor (HSPG) Cytokines Growth factors 
Unspecified HSPG 
IL-5, IL-6, IL-8, IL-10, 
CXCL12/SDF-1, TNF-α, 
and PF-4 
FGF1, FGF2, FGF4, FGF7, FGF8, FGF10, and 
FGF18; HGF, PDGF, HBEGF, Neuregulin-1, 
VEGF, BMP-7, Noggin, Hh 
SDC1–4 CXCL12/SDF-1 
FGF2, HGF, VEGF, HBEGF, Hh, Midkine, 
Pleiotrophin, TGF-β, Wnt 
GPC1–8  
FGF1, FGF2, HGF, VEGF, BMP-7, Hh, Wnt, 
TGF-β, Midkine, IGF 
Agrin  FGF2 
Perlecan  FGF2, FGF7 
TβRIII  FGF2, TGF-β1, TGF-β2, TGF-β3, inhibin, BMP-7, 
BMP-2, BMP-4, GDF-5 
CD44 MCP-1 FGF2, VEGF, HBEGF, HGF 
Nrp1–2  





further accessible basic residues outside the consensus motif, which contribute to tightly 
regulate the protein functionalities, in a context and protein-specific manner.  
Besides growth factors and cytokines, HS is the native substrate for enzymes as 
extracellular endosulfatases (Sulf-1 and Sulf-2) and the endoglucoronidase heparanase, 
which can degrade or alter the structure of HS, not only supporting the tumor invasiveness 
but also increasing the availability of the bound growth factors. Relevantly, both HS and 
heparin share the same recognition sites on the heparanase sequence [34].  
Regarding heparin, its physiological role remains mostly unclear, but its storage 
within specific granule in mast cells points to a regulatory role during inflammation [35,36]. 
As animal-derived material, commonly purified from porcine intestine, unfractionated 
heparin (UFH) has been used since 1935 extensively in the clinic as anticoagulant for 
treating clotting disorders and after surgery. Its anti-thrombotic potential relies mostly on 
its high affinity for the serine protease inhibitor antithrombin III (AT). 
Independently on anticoagulation and giving its high affinity to a wide variety of proteins 
(i.e., heparanase and HS-binding proteins), more therapeutic functionalities ranging from 
anti-tumorigenic [37], anti-angiogenic [38], anti-inflammatory [39–41] and antiviral [42]. 
Nevertheless, heparin suffers from some limitations: high polydispersity and, due to its 
animal origin, the risk of contamination and disease transmission.  
Based on the affinity for heparin/HS to proteins relevant in tumorigenic cascades, 
the following chapters focus on the description of two major tumoral processes: the 
hedgehog signaling pathway and angiogenesis and their relation to HS/heparin interactions. 
1.3 The Hedgehog (Hh) signaling pathway 
As previously mentioned, the morphogen Hedgehog (Hh) interacts with HSPGs 
expressed on the cell surface and located in the ECM. Hh is the ligand responsible for the 
initiation of the Hh pathway, and it has been shown that the interaction with HSPGs plays 
an essential role in pathway regulation [43]. 
The evolutionary conserved Hh signaling pathway is one of the diverse signaling 




mammalian embryonic development, the Hh ligand expressed and released by the cell, acts 
as a morphogen, thus forming long-range concentration gradients by which regulates 
differential cells fate decisions. In embryos, Hh signaling controls cell proliferation, 
survival, tissue patterning, and vascularization. Notably, in adult tissue, the Hh pathway is 
mostly inactive or poorly activated and maintains the homeostasis of stem cells and 
pluripotent cells involved in tissue repair as mammary, skin, nervous system, lung stem 
cells and intestine [44–48]. 
Over the last decades, growing evidence suggests that mutations within the cascade 
lead to aberrant Hh pathway activation involved at various stages during initiation, 
progression, and invasion of several types of tumors [49]. Aberrant Hh signaling activation 
is commonly associated with basal cell carcinoma (BCC), the most common type of skin 
cancer, medulloblastoma (MB), the most common type of pediatric malignant primary 
brain tumor, and rhabdomyosarcoma, a sarcoma of skeletal muscles cells [50–52]. 
Despite these well-recognized cancers, Hh aberrant activation is implicated in the 
development of other cancer types such as glioma, breast, ovarian, colon, gastric, 
pancreatic, prostate, and small-cell carcinoma [53,54].  
 Sonic hedgehog (Shh) ligand 
Mutations in the Hh gene were first discovered in 1980 by Nüsslein-Volhard and 
Wieschaus with the aim to identify genetic alterations affecting segmentation and polarity 
during the development of larval bodies in Drosophila melanogaster [55]. As the name 
suggests, the Hh mutations are responsible for the generation of a “spiked” phenotype of 
the Hh mutant Drosophila larvae, where full body-denticles resemble the spines of a 
hedgehog. In contrast to Drosophila, which possesses only one Hh gene, higher organisms 
have several, and in mammals, three orthologous are conserved: Sonic hedgehog (Shh), 
Desert hedgehog (Dhh) and Indian hedgehog (Ihh). All three ligands bind equally strong to 
their receptors but elicit different biological activities [56]. Among those, Sonic hedgehog 
has gathered the highest interest due to its expression and central role in the development 




The first key component of the pathway is the Shh ligand that is initially synthesized 
as 46 kDa precursor protein consisting of two units: an N-terminal signaling element 
domain and a C-terminal protease domain. In the endoplasmic reticulum, the N-terminal 
domain undergoes autocatalytic cleavage operated by the C-terminal domain and releases 
a 19 kDa active unit, called Shh-N (Figure 3). The nascent peptide is further modified via 
two post-translational lipid modifications. The first modification is operated by the catalytic 
C-terminal domain and consists of an intramolecular cholesterol transfer on the carboxyl 
end of the N-terminal fragment [57]. The second modification is catalyzed by a O-
acyltransferase (Hhat), which modifies the peptide by the addition of a palmitoyl group at 
the Cys-24, resulting in an extremely hydrophobic molecule (Shh-Np, standing for Shh-N 
processed) [58]. The hydrophobic nature of the dually modified Shh-N enhances the 
membrane tethering of the protein, whereas the form of Shh that lacks cholesterol 
modification (Shh-Nu, Shh-N unprocessed) is easily expressed and released in the cell 
medium [59].  
Several studies showed that cholesterol modification is essential during 
development for both long-range signaling and pathway maximal activity [60–63]. 
The palmitoyl modification seems in addition being determinant for the signaling 
functionality. Mutations resulting in Shh-N lacking the palmitoyl group showed reduced 
pattern activity both in the mouse and Drosophila [62,64–66]. Curiously, the highly 
lipidated nature of Shh may seem to be in contrast with its morphogenic character; to form 
a concentration gradient, Shh should freely diffuse instead lipid modifications seem to 
decrease the ligand solubility. However, it is today clear that the modifications are parts of 
a tightly regulated process in which proteins like Dispatched (DISP), which binds to Shh 
in a cholesterol-dependent manner via a sterol sensor domain, are responsible for the release 
of the ligand (Figure 3) [49,67]. An additional secreted protein, the soluble glycoprotein 
Scube2, is implicated in Shh ligand release via alternative affinity to the cholesterol motif 
[68,69]. Additionally, the release of Shh is shown to be operated via proteolytic cleavage 
by cellular sheddases, the ADAMs (a disintegrin and metalloproteases), which remove the 
palmitoyl lipidated terminal peptide, enabling ligand solubilization [70]. Furthermore, Shh 
ligands are known to self-associate and multimerize at the cell surface membrane via both 
lipid modifications. Nevertheless, the exact contribution of each modification is still not 




formation with lipoproteins and micelles, alternatively there are internalized into 
intraluminal vesicles, which are lately secreted as exovesicles  (Figure 3) [71].  
Figure 3: Shh-N ligand synthesis and releasing routes. In the endoplasmatic reticulum, the Shh precursor 
undergoes autocatalytic cleavage followed by lipid post-translational modifications resulting in Shh-N terminal 
fragment carrying cholesterol and palmitoyl motif. Shh-N is released extracellularly via diverse mechanisms: 
1: Disp and Scube2 enable the cleavage of monomeric Shh-N via cholesterol removal, whether sheddases 
remove the palmitoyl motif. HSPGs act as protein scaffolds and participate in regulating the protein cleavage 
and facilitating Shh-N multimerization. 2: Lipidated membrane-bound Shh-N can be alternatively internalized 
into intraluminal vesicles (2b) which subsequently fuse with the plasma membrane and are released as 
exosomes (2c). 3: Binding of Shh to HSPGs might regulate the localization of Shh proteins into secreted 
lipoproteins. Picture reprinted from Ramsbottom et al. [72] licensed under Creative Commons Attribution 4.0 
International License.  
The interaction of Shh to HSPGs is known to play a central role in pathway 




colleagues provided in Drosophila the first confirmation of the role of HSPGs in Shh 
signaling. Mutation in the genes codifying for enzymes required in HS synthesis resulted 
in altered Hh signaling [73]. In 2008, Vyas and colleagues confirmed the colocalization of 
Hh nanoscale oligomers with HSPGs at the surface of the ligand producing cells [74]. 
Following, several studies described the binding of Shh to heparin/HS [75–77]. 
The interaction between Shh and HSPGs counts on the electrostatic binding between HS 
chains and the N-terminal region of Shh carrying the heparin-binding Cardin-Weintraub 
(CW) motif (Lys 32-38 for the human sequence). Experimental evidence suggests that 
HSPGs act as a scaffold, allowing Shh ligand accumulation at the surface of the ligand-
producing cell, which enables Shh multimerization and release as diffusible multimeric 
complexes [64]. Speculations about the activity of HSPGs as Shh co-receptor, concern 
prevention and promotion of signaling by stabilizing the ligand/receptor complex [78]. 
In addition, the CW motif of Shh seems to be the recognition site for Shh sheddase-
dependent cleavage and release [70]. In this perspective, several studies support the idea 
that the HSPGs via binding to the CW motif would compete with the sheddase for Shh 
release, thus regulating the ligand solubilization and thereby signaling activity [68,79]. 
Finally, a recent in vivo and in vitro study confirmed the relevance of CW binding to HSPGs 
to control ligand release and showed that soluble heparin and HS, via binding to Shh, inhibit 
its interaction to the receptor in a charge degree-dependent manner [80]. Intriguingly, other 
in vitro studies reported that the deletion of the CW reduces but does not eliminate the 
interaction between Shh and HS/heparin and does not alter Shh-induced embryonic 
patterning in vivo [81]. In this context, Chang et al. showed that also the Lys 178 (human 
sequence) is involved in the binding to heparin and that its deletion results in reduced 
pathway activity [82]. Moreover, a recent study examining the crystal structure of 
complexes formed by Shh and heparin revealed the presence of an evolutionary conserved 
GAG-binding site (Lys 87, Arg 123, Arg 153, and Arg 155- human sequence), which 
besides the CW motif, contributes to the interaction of Shh with HSPGs and additionally 




 Shh signaling cascade  
The Shh-signaling cascade, as described in Figure 4, is initiated by the binding of 
processed Shh-N to the transmembrane receptor Patched 1 (PTCH). In the absence of the 
ligand, PTCH acts as an inhibitor on a seven transmembrane-span receptor called 
Smoothened (SMO), a G-protein coupled receptor, preventing its activity, probably via 
preventing its localization on the cell surface [85]. However, the binding of Shh ligand to 
PTCH resolves its inhibitory activity on SMO, leading to SMO activation. At this point, 
while active-SMO and other down-stream pathway components translocate to a non-motile 
primary cilium structure on the cell membrane, the complex PTCH-Shh is internalized and 
degraded in the lysosomes [86]. The most relevant components at this stage are the zinc 
finger glioma-associated (GLI)-transcription factors GLI1, 2, and 3. The GLI factors are 
located at the top of the primary cilium and are activated upon SMO activation [87]. While 
GLI2 primarily functions as an activator and GLI3 mostly as a repressor [88], GLI1 acts 
only as an activator. GLI1 is negatively regulated by the binding to the Suppressor of Fused 
(SuFu), which prevents GLI1 from entering the nucleus [89]. Upon Shh pathway activation, 
SuFu-GLI complex dissociates allowing GLI to enter the nucleus [90]. In the nucleus, GLI 
activates the expression of the Shh pathway target genes via binding to the respective 
promoters. Transcription permits not only the perpetuation of the positive Shh-pathway 
feedback ( i.e., GLI1, PTCH1-2) [91] but also promotes proliferation and tumorigenesis 
(i.e., Cyclin-D1, MYCN) [92], apoptosis (i.e., BCL-2) [93], angiogenesis (i.e.,VEGFA) [94], 
epithelial-to-mesenchymal transition in metastasis (SNAIL) [95], stem cell self-renewal 
(i.e., NANOG, SOX2) [96], Notch signaling pathway (JAG1) [97] and tissue repair (FGF4) 
[98]. As well, the existence of crosstalk between the Hh pathway and Wnt signaling has 
been shown [99]. Recently, two GLI transcript isoforms have been identified: an N-terminal 
deletion (GLI1∆N) [100] and a truncated GLI1 variant (tGLI1) [101]. Notably, tGLI1 is 
expressed only in cancer cells and tissues and acts as a GLI1 gain-of-function variant, 
activating target genes (i.e., Heparanase 1 (HPA1), VEGFR2 and CD24) not regulated by 






Figure 4: Shh signaling cascade. Shh-pathway cascade activated upon binding of Shh to PTCH receptor (on 
state). The binding releases the inhibitory activity operated by PTCH on receptor SMO (off-state). SMO moves 
into a primary cilium structure along the membrane and activates GLI-transcription factors, which translocate 
to the nucleus and activate the transcription of Shh-pathway target genes. Reprinted under the permission of 
Amakye D. et al., 2013 [84].  
 Models of signaling cascade activation in cancer 
The cascade model described above mostly refers to the canonical, classical 
pathway activation via Shh ligand binding to the PTCH receptor. In cancer, a total of four 
basic models of Shh signaling pathway activation have been proposed [103].  
The type I pathway cancers are characterized by non-classical signaling that harbors 
Shh-pathway driven mutations. They can be loss-of-function mutations of PTCH or SUFU 
and gain-of-function of SMO, leading to permanent ligand-independent cascade activation. 
The type I cancers are strongly associated with BCC [104], MB, and occasional 
rhabdomyosarcoma [105,106]. In addition to genetic mutations affecting the members of 
the cascade, multiple crosstalk pathways can lead to Shh pathway activation ligand-
independently. Examples for these interactions are reported for tumor necrosis factor-α and 
interleukin-1β, which upregulate GLI1 through the NF-κB pathway in pancreatic and breast 




cancer [107,108] and the upregulation of GLI activity by RAS/RAF/MEK/ERK and 
PI3K/AKT pathways [109].  
In the type II autocrine-juxtracrine model, there is an over-expression of Hh ligand, 
both produced and returned to the same or nearby located tumor cells, supporting cancer 
cell proliferation and survival. Additionally, high Shh ligand expression associates with 
upregulated PTCH and GLI expression [110]. In the last decades, the type II Shh pathway 
activation has been associated with a wide variety of tumors, including lung, stomach, 
breast, pancreas, prostate, liver, and brain [47,111–117].  
In type III paracrine signaling, the Shh ligand produced by the tumor cells is 
received by the stroma cells, which then feedback the tumor cells by producing and 
secreting signaling molecules (such as VEGF, IGF, PDGF, and BMPs) that further support 
cancer cells growth. Recent evidence suggests that Shh ligand overexpressing cancers 
might be refractory to the ligand while the tumoral stroma is ligand-responsive [118,119]. 
Fan and colleagues showed that prostate cancer activates paracrine Shh mechanism [120]. 
Additionally, Theunissen and Sauvage support this finding [121]. More evidence suggested 
that in pancreatic ductal adenocarcinoma (PDAC) the paracrine activation Shh signal might 
be the principle mechanism supporting tumor growth, whether tumor cells might not be 
responsive to Shh ligand themselves [119,122–124]. Lately, it has been also recognized a 
further model of Shh signaling, called type III reverse paracrine, in which Shh is secreted 
from the stroma and targets back the tumor cells. However, so far, the inverse paracrine 
model has been only observed in hematological cancers [118].  
 Shh signaling inhibitors  
In Table 2 are reported some of the most common Shh inhibitors as part of a long 
list, including more than 50 drugs with diverse targets within the signaling cascade. 
The most common targets for inhibitors design are Shh ligand, SMO receptor, and GLI 
transcription factors. To date, only three SMO-specific inhibitors, Vismodegib, Sonidegib, 
and Glasdegib, received the US Food and Drug Administration (FDA) approval. 




steroidal alkaloids and was the first SMO inhibitor discovered in 1998 [125]. Lately, the 
potential of cyclopamine in cancer treatment has been reported, and cyclopamine became 
a model drug for studying the Shh-signaling pathway [54,126]. However, low oral 








Table 2: Shh pathway inhibitors.  
Vismodegib, a cyclopamine derivative, was the first specifically designed Shh-
inhibitor synthesized in 2009. In 2012, Vismodegib received FDA approval for the 
treatment of metastatic basal cell carcinomas (BCCs) [139,140]. To date, 42 clinical trials 
using Vismodegib have been completed, and many of them investigated the anticancer 
potential of  Vismodegib in various types of cancer as pancreatic (NCT01088815)1, ovarian 
(NCT00739661), colorectal (NCT00636610), prostate (NCT02115828), lung 
(NCT00887159), to mention some. However, limitations related to SMO antagonists are 
represented by the development of therapeutic resistance linked to acquired mutations in 
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the drug-binding pocket of SMO, amplification of downstream GLI transcription factors, 
or upregulation of the Hh pathway by synergistic SMO-independent signals [127,141,142]. 
GLI inhibitors represent an emerging alternative therapy. These inhibitors not only 
act downstream of SMO, and therefore are effective likewise in tumors carrying SMO 
mutations but acting directly on GLI factors, result successful in inhibiting also the non-
canonical Hh pathway activation by other oncogenic pathways [54]. GANT58 and 
GANT61 are two small synthetic inhibitors targeting GLI. GANT61 is the most studied 
and efficient GLI antagonist. GANT61 binds to the zinc finger regions 2 and 3 of GLI1 and 
GLI2 and thereby interferes with GLI nuclear translocation and GLI-to-DNA binding, 
[143]. The anti-tumorigenic efficiency of GANT61 has been reported for several cancer 
types such as lung, breast, pancreatic cancer, and acute myeloid leukemia both in vitro and 
in vivo [137,144–146]. So far, GANT61 did not reach clinical trials.  
Direct targeting of Shh ligand, is also an emerging therapeutic strategy. Petrova and 
colleagues discovered in a screen for inhibitors of the hedgehog acyltransferase (Hhat), an 
enzyme responsible for Shh palmitoylation, the compound RU-SKI 43. [130]. The authors 
demonstrated the anti-tumorigenic potential of RU-SKI 43, also in vivo in a mouse 
xenograft model of pancreatic cancer [147]. Instead, the monoclonal inhibitory Shh 
antibody 5E1 binds to Shh with a low nanomolar affinity, preventing its interaction with 
the PTCH receptor and thereby blocking the cascade activation [148]. 5E1 caused growth 
inhibition of medulloblastoma, as well as reduces pancreatic tumor growth in mouse 
xenografts [149,150]. However, none of these Shh-inhibitors reached clinical trials so far. 
Only recently, Manikowski et al. studied the capacity of heparin and HS oligosaccharides 
to inhibit Shh-pathway activation and to reduce ligand solubilization [80]. Nevertheless, to 
date, no heparin/HS mimetics have been described as Shh signaling inhibitors.   
1.4 Tumor Angiogenesis 
As previously mentioned, HSPGs bind to several growth factors and enzymes, 
which are involved in activating and supporting angiogenesis. In a physiological context, 
angiogenesis, as a coordinated and complex process, regulates the formation of new blood 




process is known as tumor angiogenesis and represents a key factor for supporting tumor 
growth, proliferation and metastasis [151,152]. 
The first confirmation of the interconnection between angiogenesis and 
tumorigenesis was discovered in 1945 when Algire and Chalkey first concluded that the 
growth of a solid tumor must be closely connected to the development of a rich vascular 
network [153]. Almost 20 years later, in 1971, the surgeon Folkman first hypothesized that 
targeting neovascularization would block or even reduce tumor growth. His hypothesis 
based on the findings that most tumors stop growing when they reach 1-2 mm3 in size in 
an avascular state and enter a dormant viable state [154].  
 Molecular mechanism of angiogenesis: the “angiogenic switch” 
The induction of tumor vasculature is also known as the “angiogenic switch” that 
follows the “tumor dormancy” phase, which can last over the years. The angiogenic switch 
is regulated by the equilibrium between positive (pro-angiogenic) and negative (anti-
angiogenic) factors that control tumorigenic homeostasis [155]. The induction of the 
angiogenic switch occurs when the “balance” tips in favor of pro-angiogenic molecules, as 
schematically shown in Figure 5; at this point, the tumor assumes the angiogenic phenotype 
and neovascularization is induced.  
Figure 5: The “angiogenic switch”. Schematic representation of the “angiogenic switch” as a balance of pro- 




The difference between physiological angiogenesis during body development and 
pathological angiogenesis in tumors lies in the tight regulation of the angiogenic balance. 
In tumors, in fact, the balance between pro and anti-angiogenic factors is lost, leading to 
the constant growth of new tumor vasculature and loss of vessel quiescence, overall 
resulting in a highly disorganized blood vessel architecture [156]. The dysregulated 
angiogenic signals act in response to the demand of nutrients and oxygen to support tumor 
growth.  
Several stimuli contribute to the angiogenic switch. These are not only genetic 
mutations, leading to expression of oncogenic proteins and loss of tumor suppressors, but 
as well metabolic stress, such as lack of oxygen (hypoxia), low acidic pH and lack of 
nutrients, mechanical stress and immune/inflammatory response [157,158]. How these 
genetic and environmental signals play together to induce the angiogenic switch still 
remains unclear. Afterward, as a result of the angiogenic engagement, there is a reduction 
of anti-angiogenic factors parallel to a vigorous expression and release into the TME of 
several pro-angiogenic factors, such as VEGF and FGF (considered as the strongest 
angiogenic molecules), platelet-derived growth factor (PDGF), epidermal growth factor 
(EGF); transforming growth factor α-β (TGF-α-β), interleukin-8 (IL-8), metalloproteases 
(MMPs) and heparanase [159]. Once the pro-angiogenic factors are released, they 
contribute directly and indirectly to ECs activation and initiate the angiogenesis cascade.  
 Vascular endothelial growth factor (VEGF) 
One of the most known and studied cytokines, given its crucial rule in angiogenesis, 
is the factor VEGF, known as VEGF-A, discovered and cloned in 1989 by Napoleone 
Ferrara [160]. VEGF-A was first identified for its capacity to increase vascular permeability 
and therefore also called vascular permeability factor (VPF). The first insights highlighting 
the importance of VEGF in angiogenesis came from genetic targeting experiments in mice 
in 1996. These experiments showed that in case of elimination of both VEGF alleles, almost 
complete absence of vasculature structure was observed and the mice underwent earlier 




At today, VEGF-A is the most potent known angiogenic factor, involved not only 
to increase vessel leakage but also in stimulating ECs proliferation, survival, and migration. 
VEGF-A is one of the six cytokines members of the VEGF/ placental growth factor (P1GF) 
family. Notably, VEGF-A is mostly involved in angiogenesis, whether others mostly 
regulate lymphangiogenesis [152]. VEGF-A is expressed as a homodimeric protein of 45 
kDa molecular weight in four spliced isoforms (VEGF121, VEGF165, VEGF189, and 
VEGF206) with VEGF165 being the most predominant variant [163]. Except for VEGF121, 
which is a diffusible factor, all the other factors bind to heparin and HS in the ECM and on 
the cell surface [164].  
VEGF activates the ECs via binding to the specific receptors VEGFR-1 and 
VEGFR-2, which are receptor tyrosine kinases expressed exclusively on the ECs. The 
major angiogenic effects, however, are due to the binding of VEGF to VEGFR-2 (Figure 
6). The binding leads to the receptor dimerization, autophosphorylation followed by 
activation of diverse signaling proteins, such as protein kinase C (PKC), protein kinase B 
(PKB/AKT) and p38 mitogen-activated protein kinases (p38/MAPK). These effectors are 
responsible for the activation of several downstream signaling pathways that modulate 
angiogenesis. Briefly, the complex VEGF-activated network includes the 
RAS/RAF/MEK/ERK signal cascade, known for promoting growth factor-induced ECs 
proliferation, PI3K-AKT signaling, which regulates cells survival, anti-apoptotic functions 
and permeability, p38/MAPK and FAK/paxillin pathways involved in cytoskeleton 
reorganization and migration of ECs. Although it might be possible to recognize specific 
pathways following the binding of VEGF to its receptor, the activated cascades are 
intricated, and many effectors represent a high level of redundancy. As a result, a complex 
network gets activated. The activity of VEGF and the binding to its receptor is dependent 
upon the binding with HSPG co-receptors like neuropilins (as Nrp-1) or other HSPGs 
(Figure 6). The binding to HSPGs regulates not only the ligand distribution and availability 
but also enables the formation of a ternary complex (receptor/ligand/HS) controlling 
ligand/receptor stability, internalization and degradation [165–167]. In 1992 and 1994, we 
had the first confirmations that soluble heparin and cell-associated heparin-like molecules, 
even though via a weak association to VEGF, are essential for the binding of VEGF to its 
receptor [168,169]. The authors first confirmed via a cell-based ligand/receptor binding 




VEGF to its receptors, whereas only higher concentrations lead to progressive binding 
inhibition [169]. Furthermore, both VEGR2 and co-receptor Nrp-1 carry an heparin-
binding sequence supporting the binding [170,171]. This opens the doors to a more 
complex scenario for both interactions and VEGF functionality, in which HS/heparin 
enhances synergistically the binding of VEGF to its receptor and the co-receptor [172].  
 Figure 6: VEGF signaling in angiogenesis. The binding of VEGF-A to VEGFR is regulated as well by the 
interaction with an HSPG co-receptor like neuropilins (Nrp-1) and other HSPGs. Upon the receptor-ligand 
binding, the receptor undergoes dimerization and autophosphorylation of tyrosine residues on the kinase 
domain, which then activate several down-stream cascades. In the picture, some of the most relevant 
intracellular activated pathways are schematically represented.  
 Fibroblast growth factors (FGFs) 
In mammals, the family of fibroblast growth factors (FGFs) is composed of 18 
different proteins (FGF1-FGF10 and FGF16-FGF23) which can be further categorized into 
six groups with five paracrine subgroups and one endocrine subgroup, based on the 




basic FGF) are paracrine factors and constitute the prototype members of this family 
[174,175].  
The FGFs are involved in the regulation of many processes involving cell growth, 
migration and cell differentiation in embryonic development, as well as angiogenesis and 
wound healing in complex diseases, such as cancer. Both FGF1 and FGF2 factors are 
reported to stimulate migration and proliferation of ECs in vivo and to present anti-
apoptotic activity [176,177].  
The molecular characterization of FGFs dated 1980 when Shing and colleagues, in 
a search for angiogenic molecules secreted by cancer cells, identified FGFs molecules via 
heparin affinity chromatography [178]. The discovery led emerge another characteristic of 
the FGFs: besides their high angiogenic potential, they show a high affinity to heparin and 
HSPGs located in the ECM or at the cells surface. The binding with HSPGs serves again 
as a reservoir for growth factors and protects them from proteolytic degradation. 
In the context of HSPGs-protein binding, the interaction with FGF is the most well-studied 
example (Figure 7).  Like VEGF, also for FGFs, the HSPGs act as co-receptors presenting 
heparin-binding domain on both receptor (tyrosine kinase receptors FGFR1-4) and ligand, 
enabling the formation of a ternary complex [179]. Upon the binding of FGFs, HSPGs to 
FGFRs, the receptor dimerizes and undergoes transphosphorylation. The phosphorylation 
results in the activation of effectors proteins as Grb2, SHP2, and Gab1 which enable the 
activation of several downstream cascades involved in angiogenesis (Figure 7) [173]. 
In brief, the pathways RAS/RAF/MEK/ERK and p38/MAPK regulate cell proliferation, 
differentiation, and migration; the PI3K/Akt pathway is essential for controlling cell 
survival and other relevant processes, whereas the activation of PLCγ, followed by IP3 
recruitment, controls Ca2+ cellular release.  
The complex interplay of FGFs with several molecules may explain the differential 
functionalities of FGFs, capable of eliciting different effects on the same cell line in a 
specific context-dependent manner [180]. In addition, FGFs differently than VEGF, are 
pleiotropic molecules capable of acting on a variety of cell types; a property which might 
reflect the capacity of FGFs to modulate angiogenesis by regulating various cell to cell 




Figure 7: FGFs signaling in angiogenesis. The activation of FGF-signaling depends upon the binding of FGF 
ligand to FGFR and to HSPGs to both receptor and ligand (ternary complex). Activation leads to receptor 
dimerization and autophosphorylation of the tyrosine residues on the kinase domain. The phosphorylation 
controls the activation of several intracellular signals, as schematically represented in the picture.  
Concerning the function of each FGFs, several genetic studies have been performed 
using knock-out mice, but all failed in clarifying the unique function of the growth factors. 
Knock-out embryo mice Fgfr1 -/- or Fgfr2 -/- die at very early stages during development, 
further limiting the study of FGFs contribution in developmental neovascularization 
[182,183]. Additionally, neither Fgfr3 -/- nor Fgfr4 -/- knockout mice showed vascular 
deficiencies. Furthermore, in contrast to VEGF, which is a potent inducer of vascular 
permeability known to cause edema and to lead the formation of hemangiomas high 
concentrations, FGFs overexpression does not result in these damaging effects [184].  
Interestingly, FGF2 and VEGF elicit independent effects on the ECs, concerning 




in ECs and stroma cells, which is additionally required to initiate signals in response to 
FGF2. Contrarily, VEGF activity results independent of FGF2 [185]. In this sense, the 
FGFs and other growth factors simultaneously orchestrate the complex angiogenic 
response. 
 Heparanase  
As previously mentioned, invasion and metastasis of cancer cells involve the 
degradation of ECM that is predominantly composed of collagens, laminins, fibronectin, 
vitronectin, and HSPGs. Cancer cells, via the combined activity of metalloproteases 
(MMPs), endoglycosidases as heparanase, serine, and cysteine proteases, enable the 
degradation and remodeling of the ECM. Heparanase is a mammalian enzyme (endo-β-
glucuronidase) that degrades HS of proteoglycans, thereby enabling cell migration and 
egress from blood vessels. Thus, heparanase plays a key role in supporting cancer 
metastasis, angiogenesis, and inflammation  [186–189].  
The direct role of heparanase in angiogenesis, similarly to its metastatic function, is 
linked to the degradation of the HS chains of the subendothelial capillary basement 
membrane, which enables the ECs invasion and movement toward the angiogenic stimuli 
during tumor growth. Besides the direct role of heparanase in angiogenesis, the enzyme 
also regulates indirectly the angiogenic signaling cascade by releasing HS-bound 
angiogenic growth factors as FGFs, VEGF and by generating HS fragments which promote 
FGFs/VEGF-receptor binding, dimerization, and signaling [190]. 
At first, the activity of mammalian heparanase enzyme, initially purified from 
human placenta and platelets [191,192], was primarily associated with a group of proteins 
commonly described as endoglycosidic enzymes capable of degrading HS, named 
heparanases. Up to now, only one single genetic sequence codifying for human heparanase 
(heparanase-1, HPA1) is recognized, thanks to the cloning studies carried out in 1999 
independently by several groups, which resulted in the same cDNA sequence [193–196].  
The genetic sequence of heparanase encodes for a 61.2 kDa not-active protein 




that non-covalently associate into a hetero-dimeric form, constituting the active heparanase. 
Notably, the heparanase sequence has a high degree of homology between species. 
This reflects a preferential expression of heparanase as dominant endoglucoronidase and 
unique enzyme used by the cells for degradation of HS chains of HSPGs, in contrast to the 
many proteins required in biosynthesis and modification of HS.  
Heparanase localizes in the cells primarily within the endocytic vesicles, both late 
endosomes and lysosomes, assuming a perinuclear localization [197]. In these vesicles, the 
latent heparanase is converted into the active enzyme, therefore translocated to the cell 
surface and/or secreted to the ECM, where it elicits its pro-angiogenic and prometastatic 
function via HS degradation [198]. Regarding its enzymatic activity, heparanase catalyzes 
the hydrolytic cleavage at specific sites within the internal glycosidic bonds of GlcA, 
producing 5-7 kDa fragments. Several studies have been performed to define the substrate 
specificity for heparanase/HS recognition. It is generally accepted that heparanase cleavage 
occurs between a GlcA and an N-sulfoglucosamine residue presenting both a 3-O-sulfo or 
6-O-sulfo group [199] and that additionally, the minimum recognition sequence is a 
trisaccharide (Figure 9).  
Figure 9: Cleavage of HSPGs by heparanase. Top: Heparanase cleavage site within the anti-thrombin 
recognition sequence of heparin (brackets). The minimal recognition sequence for substrate recognition by 
heparanase locates within a highly sulfated trisaccharide GlcN-GlcUA-GlcN. Cleavage takes place between 
GlcUA and GlcN that is 6-O-sulfated or 3, 6-O-disulfated. Bottom: Heparanase cleavage controls the 
availability of both HS-bound growth factors and HS-fragments, thereby regulating ligand-receptor binding 
and respective intracellular pathways activation. Picture reprinted under the permission of Vlodavsky I. and 




Overall the studies confirmed that heparanase recognizes certain sulfation patterns 
rather than the saccharides sequence and that the cleavage takes place at the non-reducing 
side of highly sulfated domains of HS [200–203].  
The association of heparanase and cancer was initially observed in B16 melanoma 
and in T-lymphoma cells [189,204]. Since then, studies based on in situ hybridization and 
RT-PCR approaches, discovered that heparanase-1 mRNA upregulation correlates with 
increased heparanase activity and the metastatic potential in all cancer cells and tissues 
including pancreas, colon, ovary, prostate, thyroid, liver, breast, stomach, brain, salivary 
gland, multiple myeloma, and acute myeloma, for mentioning some [187,197,205–208]. 
Moreover, the high expression of heparanase associates with more aggressive tumors and 
reduction of post-operative survival time in cancer patients [207,208]. Studies showing 
increased cancer cell proliferation in case of heparanase overexpression and reduction of 
metastatic potential after heparanase silencing gave a more conclusive proof for the role of 
heparanase in cancer metastasis [209]. Besides high expression in cancer cells, heparanase 
expression is reduced in normal tissues, showing low-level preferential expression in the 
placenta, active immune cells, platelets and keratinocytes [210].  
In vitro data confirming the correlation between heparanase and angiogenesis 
derived from immunohistochemical staining of varies human tumors. The study showed 
that heparanase is preferentially expressed by ECs of capillaries and small sprouting blood 
vessels close to the tumor, in contrast to the endothelium of mature vessels, where 
heparanase was not detected [211]. More consistent in vivo investigations, revealed that 
overexpression of heparanase in tumors results in increased tumor vascularization and a 
higher degree of microvessels maturation in several subsets of tumors [211–213]. 
Moreover, heparanase might elicit angiogenic responses as cell adhesion, survival, and 
upregulation of VEGF expression, independently of its enzymatic activity [214].  
 Angiogenesis and heparanase inhibitors: focus on heparin mimetics 
VEGF and VEGF receptors are regarded as key regulators of angiogenesis. 




To date, several VEGF/VEGFR inhibitors have been discovered, ranging from monoclonal 
antibodies, peptide inhibitors and small molecules inhibitors targeting the receptor tyrosine 
kinase domain on VEGFR [215]. 
The most famous anti-angiogenic drug is still today the monoclonal antibody 
Bevacizumab approved in 2004 by the FDA to treat metastatic colorectal cancer in 
combination with standard chemotherapy [216]. Bevacizumab binds to VEGF-A impairing 
the binding to its receptor. Besides its clinical efficacy, Bevacizumab treatment is often 
associated with several side effects, also due to the inhibition of VEGF signaling in normal 
endothelial cells highly expressing VEGFR [217]. Moreover, long term Bevacizumab 
treatment associates with the development of drug resistance [218].  
As previously mentioned, angiogenesis is a multilevel complex cascade where 
several growth factors, and not exclusively VEGF, orchestrate the angiogenic response by 
cooperatively regulating multiple pathways. Furthermore, the complexity of this process 
additionally relies on the redundancy of function elicited by the growth factors. In this view, 
scientists were encouraged, to develop drugs that have multiple targets within angiogenic 
cascade, to achieve higher therapeutic efficacy. The capacity of HS to bind and regulate 
several pro-angiogenic factors like VEGF and FGFs, and to act simultaneously as a direct 
substrate of heparanase, made them attractive candidates for the development of anti-
angiogenic molecules. In this context, an ideal HS/heparin mimetic drug would antagonize 
for the binding of growth factors (i.e., VEGF and FGFs) to HSPGs, thereby preventing the 
formation of a ternary complex of HS/growth factor/receptor. Besides, such a compound 
would downregulate the enzymatic activity of heparanase via competing with its natural 
substrate, reducing metastasis and as well interfering with the release of HS-bound growth 
factors.  
Heparin has been logically identified as a potential anti-angiogenic compound and 
heparanase inhibitor. However, its high anticoagulant activity limits its use in cancer 
therapy [219]. In view of overcoming the limitations related to heparin, besides retaining 
high affinity to heparanase, several heparin mimetics and modified heparins have been 
designed. These low/non-anticoagulant heparins are, up to now, the most studied 
heparanase inhibitors. Interestingly, most of these molecules which reached various stages 




angiogenic growth factors, as VEGF and FGFs, via competing for their binding to HS. 
In Table 3 some of the most relevant heparin-like angiogenesis inhibitors in development 
are reported.   
Table 3: Anti-angiogenic heparin mimetics. Synthetic heparanase inhibitors that also interfere with the 
activity of further pro-angiogenic factors.  
When looking at the achievements in clinical trials, PI-88 (Mopafostat) (Figure 10) 
reached a considerable success among the anti-angiogenic heparin-like drugs, having 
undergone multiple phase I and II trials for the treatment of several cancer types [221–223]. 
In 2017, the drug progressed to phase III trials for hepatocellular carcinoma 
(NCT01402908). However, although the trial was discontinued, as the drug did not show 
sufficient efficacy, the authors claimed promising features of PI-88 in a single or 
combinatory therapy in future trials [220]. PI-88 is a heterogeneous mixture of highly 
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sulfated monophosphorylated mannose oligosaccharides, with tetra- and pentasaccharides 
as major components, isolated from the yeast Pichia holstii NRRL Y-2448 [225]. PI-88 
showed a high inhibitory capacity toward heparanase (IC50= 8 nM) [235]. Besides, PI-88 
revealed also a high affinity for VEGF and FGFs growth factors, preventing thereby the 
activation of the signal [236]. Hossain and colleagues showed that PI-88 inhibits two human 
extracellular endoglucosamine 6-sulfatase (Sulf-1 and Sulf-2) in a concentration-dependent 
manner [237]. Thus, the wide target's spectrum contributes to the high anti-angiogenic and 
antimetastatic potential of PI-88. This heparin mimetic has however anti-coagulant 
properties as the drug significantly stimulates the release of tissue factor pathway inhibitor 
(TFPI) [238], a strong anticoagulant protein. Therefore, novel derivates of PI-88, as the 
series of PG500 have been designed to its anticoagulant activity [235]. PG500 are sulfated 
oligosaccharides linked to a lipophilic moiety (such as aglycone) and show a greater 
antimetastatic and antiangiogenic effect compared to PI-88 [239].  
Figure 10: Chemical structure of PI-88. Reprinted under the permission of Johnstone K. D. et al. [236].  
1.5 Heparin mimetic: the dendritic polyglycerol sulfate (dPGS) 
Despite derivates of unfractionated heparin, as low molecular weight heparin 
(LMWH), have been in the last decade substituting UFH in clinics, giving their reduced 
heterogeneity and less variable pharmacokinetics, these drugs are not free of the 
disadvantages related to heparin [240]. As already mentioned, much effort has been made 
in order to overcome the limitations of the heparin and maximizing its therapeutic potential, 




These compounds, which are usually anionically characterized by a high level of sulfation, 
resemble the structure of GAGs as heparin and/or HS, and via competition for the binding 
with the natural ligands or substrates, aim to interfere with the multiple cascades regulated 
via HS/heparin-binding proteins and enzymes. Shifaza M. and Coombe D R. offer a 
detailed review about heparin mimetics and their therapeutic efficacy [26]. Generally, the 
synthetic nature of these drugs offers several advantages over heparin, all related to an 
easier control over the structure, resulting in increased purity and homogeneity, scalable 
synthesis, reduced polydispersity, tunable functionalization and degree of sulfation; all 
characteristics which enable rational design of higher selective and potent anti-tumorigenic 
drugs.  
In the context of designing a fully synthetic heparin mimetic, Türk H. et al. in 2004 
synthetized highly branched polysulfated molecules based on a dendritic polyglycerol 
(dPG) scaffold, called dPGS [241]. Precedent studies investigating on dPG, confirmed its 
great potentiality in biochemical applications given its elevated biocompatibility and access 
to high-level functionalization, potentially enabling multivalent interactions [242–244]. 
Via one step-synthesis involving sulfation via sulfur trioxide-pyridine complex (SO3∙py) 
of dPG, dPGS was produced as fully synthetic anionic highly branched polymers (Figure 
10). 
Figure 10: Representative and idealized structure of dendritic polyglycerol sulfate (dPGS). Picture 





 dPGS as inhibitor of inflammation   
Türk at al. used three different molecular weight dPG core structures (2.5, 5, and 10 
kDa) and realized equal sulfation of ~80%. Designed as heparin analog dPGS with a core 
size of 5 kDa showed only an anticoagulant activity of 34% compared to heparin, but a 24-
fold increase in anti-complement activity[241]. 
Substantial proofs of the anti-inflammatory potential of dPGS were presented by 
Dernedde et al., which confirmed the complement inhibition and anti-inflammatory activity 
of dPGS in vivo. [246]. In the context of inflammation, leukocytes are recruited from the 
bloodstream to the endothelium, followed by their extravasation toward the inflamed 
tissues. In this process, the adhesion molecules selectins enable the interaction between the 
circulating leukocytes and endothelium. Via surface plasmon resonance (SPR)-based 
affinity assays the authors showed that dPGS, binding to L- and P- selectins (expressed on 
leukocytes and endothelial cells, respectively), competitively inhibits the binding to their 
native ligand, the P-selectin glycoprotein ligand-1 (PSGL-1), with a binding inhibition IC50 
value up to the picomolar range. The capacity of dPGS to interfere with selectin-binding 
relies on electrostatic interaction: both L- and P- selectin carry a basic binding pocket 
involved in the recognition of the physiological ligand PSGL-1, which binds to them via 
its anionic tyrosine sulfate residues. Consequently, dPGS as a highly anionic molecule 
would compete for the binding with the positively charged ligand recognition site on the 
selectins. Moreover, the high number of sulfated groups would increase the binding affinity 
resulting in a multivalent binding effect. The work provided in vivo evidence for the anti-
inflammatory potential of dPGS in a skin inflammation mouse model. Moreover, based on 
the SPR-measured affinity of dPGS to complement factors C3 and C5, the authors 
confirmed in vivo reduced generation of anaphylatoxin C5a (as a proteolytic product of C5 
factor) in a mouse model for complement activation. Silberreis et al. recently provided a 
detailed analysis of dPGS-mediated complement inhibition [247].The above-mentioned 
work and a further study verified the dependency between size and degree of sulfation; both 
bigger core size and a higher degree of sulfation are responsible for increasing selectins 
inhibitory binding [246,248]. These findings support the idea that the dPGS-dependent 




shielding of the carbohydrate-binding site. In contrast, increasing the level of branching 
from 60 to 100% results in a 100-times lower binding affinity toward L-selectins [249].  
Further studies focused on diseases result from inflammation models such as 
osteoarthritis and rheumatoid arthritis. Gröger et al., applied diverse anionic functionalized-
dPG-dye-labeled compounds, confirmed penetration in the bone tissue and a remarkable 
affinity for dPGS to cartilage [250]. This aspect was further explored by Reinmann et al. 
which confirmed a high affinity of dye-labeled-dPGS to native and inflamed cartilage, 
suggesting a potential use of dPGS for cartilage targeting purposes [251]. Schneider et al. 
focused on dPGS treatment in an osteoarthritis model in rats [252]. Given the high affinity 
to selectins and complement factors, dPGS-dye-labeled structures were used to specifically 
target inflammation sites in vivo. Both a mouse model of collagen-induced rheumatoid 
arthritis and mice with acute allergic asthma visualized the accumulation of a dye-labeled 
dPGS at the inflamed site [253,254]. However, a close look at the biodistribution of 
radiolabeled-dPGS, demonstrated accumulation of the compound in the liver and spleen, 
even after 3 weeks of injection [255]. To overcome this problem Reiman et al. synthetized 
shell cleavable dPGS, which promised good degradation in vitro [256]. Remarkably, one 
variant, the dPG-thioglyceryl pentanoatyl sulfate (dPGTPS), containing a long, flexible and 
hydrophobic linker, including an ester functionality to enable enzymatic cleavage, showed 





Figure 11: Schematic representation of dPGTPS structure. dPG-thioglyceryl pentanoatyl sulfate (dPGTPS) 
(3) synthetized as functionalized dPG (1)-based polyanion (dPG scaffold is represented as idealized fragment). 
Comparison to dPG functionalization leading to dPGS synthesis (2). Modified under the permission of 
Reimann et al. [256].  
 Potential use of dPGS in cancer therapy  
Given the rapid uptake and reduced toxicity of dPGS, confirmed by several studies 
conducted both in non-carcinogenic and carcinogenic cell lines [250,251,257], researches 
have been focusing on studying the potential of dPGS as a cancer-drugs carrier. Sousa et 
al. showed efficient delivery of paclitaxel-dPGS conjugates and received cytotoxic effect 
in the lung carcinoma cell line A549 cells and squamous cancer cells A431 [258]. 
However, the authors observed premature drug release in plasma and in physiological 
solution. Ferber et al. overcame the problem by linkage of paclitaxel to dPGS via a pH 
cleavable hydrazone linker and successfully inhibited in vivo tumor growth in a mouse 
model of intracranial glioblastoma [259]. The glioblastoma targeting capacity of dPGS-
paclitaxel relies on the affinity of the anionic compound to P-selectins, which the authors 
confirmed to be highly expressed in a mouse model carrying either human or mouse 
glioblastoma. Notably, Zhong et al. showed potent anti-tumorigenic activity in vivo in a 
human mammary xenograft mouse model, via coupling doxorubicin to biodegradable 
micelles of sheddable dPGS [260]. The authors claimed the tumor target capacities relate 




dPGS-mediated binding of inflammation-related proteins as selectins, which are up-
regulated at the tumor site.  
1.6 Objectives  
The high grade of heterogeneity within the tumor populations, the genetic instability 
that characterizes tumor cells, together with the elevated tumorigenic pathway redundancy, 
often leads to the development of drug resistance in patients in response to single-target 
drugs treatment [261]. Nowadays, drug resistance still represents one of the main 
challenges in tumor therapy, mostly responsible for the relapse after successful initial 
treatment [262]. In this context, multitarget drugs, which show activity on a wider spectrum 
of interactors, have gained high interest, and in the last decade emerged from being 
unattractive compounds to one of the hottest topics of the last years [263,264]. 
Previously have been reported the multi-target affinity of HSPGs and their functionality in 
regulating relevant cellular processes as tumorigenesis; characteristics which made HSPGs 
promising candidates for the development of multi-target drugs.  
In this context, the main objective of this thesis was to evaluate the capacity of the 
dendritic polyglycerol sulfates, to pleiotropically interfere with multiple mechanisms 
essential for cancer progression. With the aim to interfere and counteract with HSPGs for 
the binding to proteins and enzymes regulating tumor progression, this study focused on 
the two relevant tumorigenic mechanisms known to functionally depend on HS binding: 
the Shh-signaling pathway and angiogenesis.  
With this perspective, in regard to the Shh-signaling pathway, two potential 
inhibitors will be evaluated: dPGS and a shell cleavable variant dPGTPS. The latter variant 
has been chosen in view of the degradable capacities, which makes it more suitable for 
future in vivo applications. In this context, the following sub-goals were defined: 
• the Shh ligand, as the initiator of Shh-signaling cascade, will be first 
recombinantly expressed, purified and subsequentially evaluated in binding 
affinity measurements  




• Further, the ability of the dendritic polyglycerol sulfates to reduce the 
proliferation of cancer cells, potentially Shh pathway-regulated, will be 
evaluated in both 2D and 3D cell culture model systems.  
To assess the anti-angiogenic capacity of the polysulfates, the following points will 
be addressed: 
• Determination of binding affinity of dPGS to the enzyme heparanase and 
the angiogenic growth factors VEGF, FGF1, and FGF2  
• Subsequentially, in vitro cellular and non-cellular based assays, will be 
applied to study the features characterizing the interaction between 
angiogenic factors and dPGS, intending to assess its potential as angiogenic 
inhibitor.  
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2 Materials and methods 
2.1 Materials 
 Instruments and devices  
2.1.1.1 Cell culture 
• Heraeus HERA safe Safety Cabinet (Thermo Fisher Scientific, Germany) 
• Heraeus BB16 Function line CO2 Incubator (Thermo Fisher Scientific, Germany) 
• Shaking Waterbath 1086 (GFL-Gesellschaft für Labortechnik, Germany) 
• Luna FL-Automated cell counter (Logos Biosystems, USA) 
• Axiovert 25 phase-contrast microscope (Carl Zeiss, Germany) 
• Inverted microscope Axio Observer Z1 (Carl Zeiss, Germany) 
• Luminoskan Ascent Luminometer (Thermo Fisher Scientific, Germany) 
• IncuCyte S3 (Sartorius, Germany) 
2.1.1.2 Electrophoresis 
• Thermo Block Grant QBT1 (Grant Instruments, UK)  
• PowerPac 300 Power Supply (Bio-Rad, Germany)  
• Mini Protean II electrophoresis cell system (Bio-Rad, Germany) 
• Mini Sub Cell GT System (Bio-Rad, Germany)  
• Safe Imager 2.0 Blue Light Transilluminator (Thermo Fisher Scientific, Germany) 
2.1.1.3 Spectrophotometer 
• Nanodrop ND-1000 Spectrophotometer (Peqlab, Germany) 
• SpectraMax 340PC Absorbance Microplate Reader (Molecular Devices, Germany)  
• Infinite M200 microplate reader (Tecan Trading, Switzerland) 
2.1.1.4 Western blot 
• Trans-Blot Cell (Bio-Rad, Germany)  
• Siemens 13 × 18 Cassette (Siemens, Germany) 
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• Optimax X-Ray Film Processor (Protec Medizintechnik, Germany) 
2.1.1.5 Centrifuges 
• Eppendorf centrifuge 5417C (Eppendorf, Germany) 
• Eppendorf centrifuge 5417R (Eppendorf, Germany) 
• Heraus Varifuge 3.0 (Thermo Fisher Scientific, Germany) 
• Heraus Megafuge 2.0 R (Thermo Fisher Scientific, Germany) 
2.1.1.6 Other devices 
• BIAcore X100 instrument (GE Healthcare, Sweden) 
• Heraeus B6 Incubator (Thermo Fisher Scientific, Germany) 
• Orbital Shaker 3016 (GFL-Gesellschaft für Labortechnik, Germany) 
• C25KC incubator shaker (New Brunswick Scientific, Germany)  
• Thermal Cycler 2720 (Thermo Fisher Scientific, Germany)  
• Mini-Shaking Oven OV3 (Biometra, Germany) 
• Wesbart IS89 Multi Shelf Shaker Incubator (Wesbart, UK)  
• IKA MS2 Minishaker Vortex mixer (Ika, Germany) 
• IKA Microplate Shaker MTS 4 (Ika, Germany) 
• Rotation vacuum concentrator Rvc 2-25 (Martin Christ, Germany)  
• Light plate 41x26 cm, 220 V (Rex, Germany) 
• Polymax 1040 platform shaker (Heidolph, Germany) 
• ABI PRISM 310 Genetic Analyser (Advance Biolabs Service, Germany) 
• Gel dryer model 583 (Bio-Rad, Germany) 
 Consumables 
2.1.2.1 Western blot 
• Photographic paper Amersham Hyperfilm ECL (GE Healthcare, Sweden) 
• Nitrocellulose membrane Hybond-C Extra (GE Healthcare, Sweden) 
• Whatman cellulose chromatography (GE Healthcare, Sweden) 
2.1.2.2 Chromatography 
• Poly-Prep Chromatography Columns (Bio-Rad, Germany) 
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• Sephadex G-25 PD10 desalting column (GE Healthcare, Sweden) 
• Amicon ultra-4 centrifugal filter-3 kDa MWCO (Merck, Germany) 
• NucleoSEQ chromatography columns (Macherey-Nagel, Germany) 
2.1.2.3 Cell culture 
• Culture dish 100x20 mm (Corning, USA)  
• T25, T75, T175 tissue culture flasks (Corning, USA) 
• Tissue Culture Plate 96 Well Standard (Sarstedt, Germany)   
• Nunc F96 MicroWell white plates (Thermo Fisher Scientific, Germany) 
• Cellcarrier spheroids ULA 96-well microplates (PerkinElmer, Germany) 
• µ-Slide Angiogenesis ibiTreat, 10 µl volume (Ibidi, USA) 
• 50, 15 ml Centrifuge tubes High Clarity (Falcon, USA) 
• 1, 2, 5, 10, 25 ml Serological pipettes (Falcon, USA) 
• Millex-GP Syringe Filters 0.22 µm (Merk, Germany) 
2.1.2.4 Other consumables  
• Streptavidin precoated SA-sensor chip (GE Healthcare, Sweden) 
• Nunc-Immuno Module 8 well-strips (Thermo Fisher Scientific, Germany)  
 Chemicals 
2.1.3.1 Plasmids 
• Human Shh cDNA clone (Sinobiological, China) 
• pcDNA6/V5-His A plasmid (Thermo Fisher Scientific, Germany) 
2.1.3.2 Primers 
• The primers were synthetized and HPLC purified by Metabion International GmbH 
(Germany). For the sequence of Shh-N primers in bold are reported the base pairs 
(bps) complementary to target plasmid vector (pcDNA6/V5-His A), highlighted in 
grey the Kozak sequence, underlined the sequence of homology for the target gene 
Shh-N.  
• Shh forward: 5´-GGG AGA CCC AAG CTG GCT AGC GCC ACC ATG CTG 
CTG GCG GCG AGA TGT CTG-3´ 
• Shh reverse: 5´-TCA ATG GTG ATG GTG ATG ATG ACC GGT GCC TCC 
CGA TTT GGC CGC CAC-3´. 
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• Forward primer binding at the T7 promoter: 5'-TAA TAC GAC TCA CTA TAG-3' 
• Reverse primer binding at the BGH site: 5´-TAG AAG GCA CAG TCG AGG-3' 
2.1.3.3 Antibodies  
• Human Shh-N terminus polyclonal antibody goat IgG (R&D Systems, Germany) 
• Polyclonal rabbit anti-goat immunoglobulins/HRP (Dako, Germany) 
2.1.3.4 Proteins and enzymes 
• Albumin fraction V biotin-free (Carl Roth, Germany) 
• Bovine serum albumin (BSA) (Albumin Standard, Thermo Fisher Scientific, 
Germany) 
• Recombinant human Heparanase/HSPE (R&D Systems, Germany) 
• Human acidic fibroblast growth factor FGF1 (PeproTech, Germany) 
• Human basic fibroblast growth factor FGF2 (PeproTech, Germany) 
• Human vascular endothelial growth factor VEGF165 (PeproTech, Germany) 
• Restriction enzymes NheI and AgeI (Thermo Fisher Scientific, Germany) 
• Phusion hot start II High-Fidelity DNA Polymerase (Thermo Fisher Scientific, 
Germany) 
2.1.3.5 Electrophoresis reagents 
• DNA gel stain SYBR (Thermo Fisher Scientific, Germany) 
• Coomassie Brillant blue G-250 (AppliChem, Germany) 
• PageRuler Prestained Protein Marker (Thermo Fisher Scientific, Germany) 
• Kb Plus DNA Ladder (Thermo Fisher Scientific, Germany) 
2.1.3.6 Sequencing reagents  
• BigDye Terminator 5× Sequencing Buffer (Thermo Fisher Scientific, Germany)  
• BigDye Terminator Mix (Thermo Fisher Scientific, Germany)  
• Hi-Di formamide (Thermo Fisher Scientific, Germany) 
2.1.3.7 Kits  
• Human Shh-N Quantikine ELISA kit (R&D Systems, Germany) 
• Pierce BCA Protein Assay (Thermo Fisher Scientific, Germany) 
• Zymoclean Gel DNA Recovery Kit (Zymo Research, Germany) 
• Plasmid purification: NucleoBond-Xtra Midi (Macherey-Nagel, Germany) 
• NucleoSpin plasmid Mini-prep kit (Macherey-Nagel, Germany) 
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• LDH cytotoxicity detection kit (Takara Bio, France) 
• Celltiter-Glo luminescence cell viability assay (Promega, Germany) 
• Celltiter-Glo3D cell viability assay (Promega, Germany) 
2.1.3.8 Cell culture  
• Dulbecco´s phosphate buffered saline (PBS)-CaCl2, -MgCl2 (Thermo Fisher 
Scientific, Germany) 
• Dulbecco´s Modified Eagle Medium-DMEM (Gibco-Thermo Fisher Scientific, 
Germany) 
• EGM2-Endothelial growth medium -2 Bulletkit (Lonza, Switzerland) 
• 0.25% Trypsin-ethylenediaminetetraacetic acid- EDTA (Gibco-Thermo Fisher 
Scientific, Germany) 
• Trypsin/EDTA 0.04%/0.03% (Promocell, Germany)  
• Trypan blue stain 0,4% (Invitrogen-Thermo Fisher Scientific, Germany)  
• Penicillin/Streptomycin (Pen/Strep) (Gibco-Thermo Fisher Scientific, Germany) 
• Sodium pyruvate (Gibco- Thermo Fisher Scientific, Germany) 
• Zeocin (Invitrogen- Thermo Fisher Scientific, Germany) 
• Geneticin G-418 (Biochrom, Germany) 
• Fetal Bovine Serum-FBS (Gibco- Thermo Fisher Scientific, Germany) 
• Horse serum (Gibco, Thermo Fisher Scientific, Germany) 
• Cultrex reduced growth factor basement membrane extract (BME) (Trevigen, UK) 
• Beetle Juice luciferase firefly (PJK Biotech, Germany) 
• Lysis juice for luciferase assay (PJK Biotech, Germany) 
• Lipofectamine 3000 reagent (Thermo Fisher Scientific, Germany) 
2.1.3.9 Other chemicals  
• Cell proliferation reagent water-soluble tetrazolium salt (WST-1) (Merck, Germany) 
• Suramin sodium salt (Sigma Aldrich, Germany) 
• HBS-EP running buffer (GE Healthcare, Sweden) 
• pNPP (para-nitrophenyl phosphate) alkaline phoshate substrate (Sigma Aldrich, 
Germany) 
• HisPur Ni-NTA resin (Thermo Fisher Scientific, Germany) 
• cOmplete (EDTA)-free Protease Inhibitor Cocktail (Roche, Germany) 
• Imidazole (Carl Roth, Germany) 
• EDTA (Carl Roth, Germany) 
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• Tween 20 (Bio-Rad, Germany) 
• Triton X-100 (Bio-Rad, Germany) 
• Tris (hydroxymethyl) aminomethane (Tris)-Base (Santa Cruz Biotechnologies, 
Germany) 
• Tris-HCl (Serva, Germany) 
• Potassium chloride (Merck, Germany) 
• Heparin, sodium salt, porcine intestinal mucosa (Merck, Germany) 
• Silver nitrate (Sigma Aldrich, Germany) 
• Formaldehyde solution 37% wt in H20 (Sigma Aldrich, Germany) 
• Ethanol, denatured (Carl Roth, Germany) 
• Tango buffer 10X (Thermo Fisher Scientific, Germany) 
• Ampicillin (Amp) sodium salt (Carl Roth, Germany) 
• Dimethylsulfoxide (DMSO) (Carl Roth, Germany) 
• GANT61 (Sigma Aldrich, Germany) 
 Bacterial strains  
• Escherichia coli competent bacteria DH5α 
 Cell lines 
• A549, human non-small cell lung cancer cells (ATCC, Germany) 
• HEK293, human embryonic kidney cells (ATCC, Germany) 
• MIA-PaCa-2, human pancreatic cancer cell line (ATCC, Germany) 
• MCF-7, human breast cancer cells (ATCC, Germany)  
• PANC-1, human pancreatic ductal carcinoma (Leibniz-Institut DSMZ, Germany) 
• Sonic hedgehog light 2 (ShhL2) cells, mouse fibroblasts NIH3T3 co-transfected with 
8XGLI-luciferase reporter and renilla control gene (from James K. Chen, Stanford 
University, USA) 
• C3H10T1/2 Clone 8, mouse embryonic fibroblasts (ATCC, Germany) 
• HUVECs pooled donors human endothelial umbilical vein cells (Lonza, 
Switzerland) 
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 Computer Software  
• AnaSP, spheroids open-source analysis program [265] 
• BIAevaluation software 4.1.1. (GE Healthcare, Sweden) 
• IncuCyte analysis program (v2019B) (Sartorius, Germany) 
• Angiogenesis analyzer ImageJ macro (https://biii.eu/angiogenesis-analyzer-imagej) 
• GraphPad Prism 5 (GraphPad Software, USA) 
• ApE, open-source DNA editor program 
(http://jorgensen.biology.utah.edu/wayned/ape/)  
2.2 Molecular biology methods 
 Transformation  
Plasmid transformation was performed in E. coli strain DH5α competent cells to 
enable plasmid replication and cloning. Briefly, 1 µl plasmid DNA (10 µl for cloning) was 
added to 50 µl stock of competent DH5α cells on ice. The transformation was carried out 
by heat shock (1 min on ice, 1 min at 42°C, 10-30 min on ice). Following, the bacteria 
suspension was added to 300 µl Luria Bertani (LB) medium (10 g/l pepton, 5 g/l yeast 
extract, 10 g/l NaCl, pH 7.0) in the absence of selective antibiotic. The mixture was 
incubated for 45 minutes at 37°C under shaking (200 rpm). A 37°C pre-warmed LB-agar 
plate (LB medium with 15g/l agar), containing 100 µg/ml ampicillin antibiotic, was 
inoculated with the 50 µl or rest volume of bacterial suspension and incubated at 37°C for 
the following 17 hours.  
 Exonuclease and ligation-independent cloning (ELIC) 
The Exonuclease and Ligation Independent Cloning (ELIC) molecular cloning 
method was used for the expression of recombinant Shh-N. This cloning technique, 
originally described by Koskela et al. [266], requires few base pairs (bps) of homology 
between the ends of both PCR amplified fragment and enzymatically digested host-vector 
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to enable ligation-exonucleases independent. In the specific, the primers for PCR 
amplification of Shh-N carry 21 bps homology with the target vector (pcDNA6/V5-His A), 
16 bps complementarity with Shh-N target gene and are additionally implemented with 6 
bps of Kozak sequence (5´-GCC ACC-3`), which helps the initiation of eukaryotic 
translation (2.1.3.2). PCR amplification mixture was set up as described in Table 4, on ice.  
Components Concentrations (µl) 
Template DNA (1 µg/µl)  1 µl 
Primers Forward and Reverse (10 µM)  1 µl each 
Phusion hot start II polymerase (HF)  1 µl 
5X Phu fusion buffer  10 µl 
dNTPs mix (10 mM)  2 µl 
Milli Q-water  34 µl 
Table 4: PCR reaction mixture  
Thereafter the mixture was transferred to a Thermal Cycler 2720 (Applied 
Biosystems) where, following the PCR program displayed in Table 5, the DNA products 
of interest were amplified.  
Step Temperature Time 
Initial denaturation 96° C 2 min 
  







Final elongation  72°C 5 min 
Table 5: Thermocycling condition for PCR  
The identity of the amplified PCR product was confirmed by agar gel 
electrophoresis (2.2.3). In parallel, the plasmid vector was linearized via enzymatic 
digestion with NheI and AgeI restriction enzymes. The digestion mixture was prepared 
according to Table 6 and performed at 37°C overnight. After restriction, agar 
electrophoresis for the digested product was performed and the DNA bands corresponding 
to the linearized plasmid were extracted from the gel and cleaned with Zymoclean Gel DNA 
recovery kit (Zymo Research), following the manufacturer´s instructions. 
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The concentration of the extracted DNA and purity was determined with Nanodrop ND-
1000 Spectrophotometer (Peqlab). 
Component Volume in 10 µl  
AgeI 0,8 µl 
NheI 0,2 µl 
Tango buffer 10X  1 µL   
DNA 330 ng/µl 3 µl (1 µg) 
Milli-Q water 5 µl 
Table 6: Enzymatic restriction mixture  
Shh-N PCR amplified fragments and linearized plasmid were mixed at optimal 1:3 
vector: insert (v/v) ratio in water at 10 µl final volume and incubated for 5 minutes at room 
temperature. Thereafter, the mixture was directly used to transform DH5a competent 
bacteria (2.2.1). Six colonies were randomly chosen, and their plasmid DNA content was 
extracted and purified with NucleoSpin Plasmid kit (Macherey-Nagel) (2.2.4). 
As initial control for successful cloning, the DNA extracted from the clones and original 
vector plasmids were digested overnight with NheI and AgeI restriction enzymes, followed 
by agar gel electrophoresis (2.2.3). The construct containing the insert were thereafter 
analyzed by sequencing (2.2.5). The plasmid result of successful cloning was further 
purified via midi-preparation (2.2.4) with NucleoBond Xtra Midi kit (Macherey-Nagel). 
The cloning products were immediately stored at -20°C and -80°C for longer storage.  
 Agarose gel electrophoresis 
Agarose gel electrophoresis was used for the separation of DNA. For the 
electrophoresis, a 1% (w/v) agarose gel was produced in Tris-acetate EDTA (TAE) buffer 
(40 mM Tris, 5 mM sodium acetate and 1 mM EDTA, pH 7.2). For enabling DNA 
visualization 1XSYBR gel stain (Invitrogen) was included. DNA samples were mixed with 
6XDNA loading buffer, loaded on the agarose gel and electrophoresis was carried out in a 
Mini Sub Cell GT (Bio-Rad) at 90 V constant for 30 minutes. DNA ladder 1 Kb (Invitrogen) 
was loaded to estimate the molecular weight migration of the DNA samples. The DNA 
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migration was visualized under light transilluminator Safe imager 2.0 (Invitrogen) and 
photographically documented.  
 Plasmids DNA extraction  
NucleoSpin Plasmid kit was used for miniprep isolation of plasmid DNA from 
bacteria clones. For this purpose, a single bacterial colony was picked from an agar plate 
containing transformants with the help of a 100 µl pipette tip, and further inoculated in 4 
ml LB medium (100 µg/ml Amp). The bacterial culture was incubated for 17 hours at 37°C 
shaking (200 rpm). The isolation was carried out following the manufacturer´s instructions.  
For purifying larger and higher purity plasmid DNA, midi-prep DNA isolation via 
NucleoBond Xtra Midi isolation kit (Macherey-Nagel) was performed. In this case, a 
colony was picked from a freshly streaked agar plate and initially incubated in 4 ml LB 
medium (100 µg/ml Amp) for 8 hours at 37°C shaking (200 rpm). This starter culture was 
further diluted 1:1000 in 100 ml LB medium (100 µg/ml Amp) and incubated at 37°C for 
17 hours under shaking conditions (200 rpm). The plasmid extraction followed the 
manufacturer’s instructions. The final isolated plasmid was diluted in de-ionized water and 
the concentration measured via Nanodrop ND-1000 Spectrophotometer (Peqlab).  
 DNA sequencing 
To confirm the successful cloning of Shh-N fragment into pcDNA6/V5-His A 
plasmid and to check the accuracy of inserted sequence, DNA sequencing using BigDye 
Terminator sequencing method (Applied Biosystems) was performed. The mixture used for 




  Materials and Methods 
45 
 
Components Concentrations (µl) 
Template DNA (100-300 ng/µl)  1 µl 
Primers Forward T7 binding (10 µM)  1 µl  
BGH Reverse primer (10 µM)  1 µl 
5XBigDye Terminator Seq. buffer  1 µl 
BigDye terminator mix  1.5 µl 
Milli Q-water 4.5 µl 
Table 7: PCR mixture for sequencing  
The PCR amplification of the products for sequencing followed the program 
displayed in Table 8. 
Step Temperature Time 
Initial denaturation 96 1 min 
  







Table 8: PCR program for DNA sequencing  
After the PCR reaction, the unincorporated dye-terminators were removed by 
NucleoSEQ chromatography columns (Macherey Nagel). Following, the samples were 
centrifuged under vacuum with Rotation-Vacuum-Concentrator (Martin Christ) for 7 
minutes at room temperature and further resuspended in 25 µl 10% Hi-Di formamide and 
incubated at 95°C for 3 minutes. Finally, the samples were sequenced with ABI PRISM 
310 Genetic Analyzer (Advanced Biolab Service).  
2.3 Protein chemistry methods 
 Protein purification via Ni-NTA affinity chromatography 
After protein expression in HEK293 cells (2.4.1) the collected supernatant was 
centrifuged 2 times at 1000 rpm for 5 minutes in a Varifuge 3.0 (Heraeus) to eliminate cell 
debris and further filtered sterile with Millex- 0.22 µm filters (Merck). The supernatant was 
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directly used for purification or stored at either 4°C or -20°C for longer storage. The 
supernatant containing Shh-N secreted protein was purified via Ni-nitrilotriacetic acid 
(NTA) agarose affinity chromatography via Ni-NTA agarose resin (Qiagen). 500 µl bed 
volume of Ni-NTA agarose was used for the purification of 10 ml supernatant. The 
supernatant was equilibrated with 20 mM Imidazole, 1% Tween 20 and 10% Tris buffer 
(pH 8.0) and loaded 3 times into the gravity column to ensure proper protein retention. The 
column was further washed once with 30-column volumes of washing buffer (PBS 1X, 40 
mM imidazole pH 7.4, 1% Tween 20, 500 mL NaCl). The protein was eluted in 5 fractions 
of 500 µl with elution buffer (PBS 1X, 250 mM imidazole pH 7.4). A further wash of the 
column was performed with a 10 column volume of elution buffer and final re-equilibration 
with 30 column volumes equilibration buffer (PBS 1X, 20 mM imidazole pH 7.4, 1% 
Tween 20). The eluted fractions were analyzed by SDS-page (2.3.2), western blot (2.3.4) 
and silver gel staining (2.3.3). For PBS buffer exchange and imidazole salts elimination, 
the eluted fractions were mixed and passed through Sephadex G-25 PD10 desalting column 
(GE Healthcare), following manufacturer’s instructions. Afterward, the protein was 
concentrated via Amicon ultra-4 centrifugal filter MWCO 3 kDa (Merck), usually reducing 
8-times the initial volume to 500 µl final volume of concentrated sample. Determination of 
protein concentration was performed via BCA-protein assay kit (Pierce), following the 
manufacturer´s instructions. Protein was stored at 4°C and in the next days used for binding 
studies.  
 SDS-page gel electrophoresis  
Shh-N protein samples were analyzed by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-page) in a 12 % (w/v) Tris-glycine polyacrylamide vertical gel on 
a Mini Protean II chamber (Bio-Rad). The composition of the 12% Tris-glycine gel is 
reported in Table 9. Electrophoresis was performed at 17 mA constant until the samples 
reached running gel and then at 21 mA constant for the rest of the protein migration. The 
electrophoresis was performed in SDS-running buffer [3.8% (w/v) Glycin, 1.2% (w/v) Tris-
Base, 0.4% (w/v) SDS, pH 8.0]. The samples were mixed with 4X sample buffer [0.25 mM 
Tris, 40% (v/v) Glycerol, 8% (w/v) SDS, 8% (v/v) 2-Mercaptoethanol, 0.004% (w/v) 
Bromophenol blue, pH 6.8] and boiled at 100°C in Thermo block (Grant Instruments) for 
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5 minutes. Page Ruler Prestained protein ladder (10–180 kDa) (Thermo Fisher Scientific) 
was used for the analysis of the protein molecular mass and as well applied for protein 
evaluation via Western blot analysis. After the SDS-PAGE, the gel was stained for about 
30 minutes with a solution of 0.1% (w/v) Coomassie Blue G-250 (AppliChem) in 40% 
(v/v) methanol and 10% (v/v) acetic acid, and destained for further 30 minutes in a solution 
of 20% (v/v) ethanol and 10% (v/v) acetic acid. 
Components  12% Running gel Stacking gel 
ddH20 1.64 mL 785 µl 
1.5 M Tris HCL (pH 8.8) 1.25 mL - 
0.5 M Tris HCL (pH 6.8) - 415 µl 
30 % Acrilamide  2 mL 265 µl 
10% SDS 50 µL 16.65 µl 
10% APS 50 µl 16.65 µl 
Temed 6.7 µL 3.35 µl 
Table 9: Composition of dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-page) gel  
 Silver gel staining of SDS-page gel 
Silver gel was used to verify the purity of the Shh-N expressed protein, after the 
electrophoretic separation via SDS-page gel (2.3.2). In this method, after performing SDS-
electrophoresis, the gel was exposed to a dual fixation: first via incubation for 20 min in 
50% (v/v) Ethanol and 10% (v/v) acetic acid, second for 25 min incubation in 30 % (v/v) 
Ethanol and 0.5 M sodium acetate trihydrate solution, under constant slow-speed shaking 
on Orbital Shaker 3016 (GFL- Gesellschaft für Labortechnik) . Following a 3-times wash 
in ddH20 for 10 minutes each, the gel was incubated in freshly prepared silver staining 
solution [0.1% (w/v) silver nitrate and 0.01% formaldehyde (37%)] for 40 minutes. 
Subsequentially, the gel was rinsed in ddH20 and developed after incubation for 5 to 10 
minutes in developing solution [2.5 % (w/v) sodium carbonate pH 11.2 and 0.01% 
formaldehyde (37%)], stopped upon addition of 0.05 M EDTA. 
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 Western blot 
Proteins were separated by SDS-PAGE 12% (w/v) gel and then transferred at 300 
mA constant for 30 minutes to a Hybond C-extra nitrocellulose membrane (GE Healthcare) 
in Tris-glycine buffer [25 mM Tris, 191.8 mM glycine in 10% (v/v) methanol], placed in a 
Trans-Blot Cell (Bio-Rad). To avoid unspecific binding, the membrane was blocked for 30 
min in blocking solution TBST [Tris-saline buffer (TBS) and 0.1% Tween 20) with 5% 
(w/v] skim milk powder. Afterward, the membrane was incubated with the polyclonal 
human Shh-N antibody (R&D Systems) overnight at 4°C under gentle shaking on a rocker. 
The membrane was then washed in TBST solution for 3 times of 10 min each and 
subsequentially incubated with polyclonal rabbit anti-goat immunoglobulins/HRP (1:5000 
diluted) (Dako) for 30 min. The membrane was washed again 3 times with TBST for 10 
min each washing step. The binding of the secondary antibody on the membrane was 
visualized via incubation with chemiluminescence reagents mixture described in the 
following table (Table 10).  
Solution A 0.25 mg/ml luminol in 0.1M Tris-HCL (pH 8.6) 
Solution B 1 mg/ml p-Coumaric in DMSO 
Solution C H2O2 
Table 10: Mixture for the western blot chemiluminescence reaction  
After 30 min exposure, the photographic paper Amersham Hyperfilm ECL (GE 
Healthcare) was developed by an Optimax X-Ray Film Processor (Protec Medizintechnik).  
 Surface plasmon resonance 
Surface plasmon resonance (SPR) measurement was performed on a Biacore X100 
(GE Healthcare) operated using BIAevaluation software 4.1.1. The measurements were 
carried out in HBS-EP buffer (GE Healthcare) with streptavidin-precoated (SA) sensor chip 
(GE Healthcare) coupled to dPGS-or dPGTPS-biotinylated molecules. The synthesis of 
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dPGS-biotin followed the procedure described somewhere else [267]. dPGTPS-biotin was 
kindly provided by Ph.D. candidate Suman Chowdhury (Freie Universität, Berlin). The 
measurements were carried out at 25°C constant temperature. Prior the immobilization of 
the dendritic polyglycerol sulfates-biotin, the chip was pretreated with three 5µl injections 
of 50 mM NaOH in 1 M NaCl at 5 µl/min to remove any unspecific bound contaminants, 
followed by a rinse with 40 µl of HBS-EP buffer at 30 µl/min. In the case of Shh-N and 
heparanase affinity measurements, dPGS/dPGTPS- biotinylated molecules were 
immobilized on one of the two flow cells to a level of ~400 RU, while for control the other 
cell flow was left empty. In the case of binding measurements for dPGS to angiogenic 
growth factors, dPGS-biotin was immobilized at lower ligand concentration (140~RU), 
whereas dPG-biotin was immobilized on the surface to rule out unspecific binding. The 
proteins were diluted as well in HBS-EP buffer [0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 
mM EDTA, 0.005% (v/v) Surfactant P20] at various reported concentrations. Affinity was 
determined by single-cycle kinetics (SCK) measurements. Five ascending protein 
concentrations were injected consecutively at a constant flow rate of 30 µl/min five for 180 
s followed by dissociation time of 600 seconds and final regeneration with 4M MgCl2 
solution with a contact time of 120 s. For FGF2, in order to reduced unspecific bindings, 
the amount of NaCl in HBS-EP buffer was double to a final concentration of 0,3 M.  
 Heparanase activity assay  
The assay based on the measurement of reducing disaccharide products catalyzed 
by heparanase cleavage of the synthetic heparin oligosaccharide fondaparinux. A method 
originally described by Hammond et al. [268], which was here applied with minor 
variations. Initially, Nunc-Immuno Module 8 well-strips (Thermofisher) were coated for 2 
hours at 37°C under low speed shaking on IS89 shaker incubator (Wesbart) with a solution 
containing 4% (w/v) BSA in PBST (PBS with 0.05% Tween 20, pH 7.4.). Thereafter the 
strips were washed 3 times with PBST, dried and stored at 4°C for up to 1 week. 
Human heparanase (R&D Systems) was diluted in 40 mM Sodium acetate buffer (pH 5.0) 
at the concentration of 5 nM and incubated with 1 to 10 nmoles fondaparinux to a final 
volume of 100 µL per well. In the case of inhibition studies, dPGS was incubated 5 min 
with heparanase prior assay beginning, upon addition of 100 µM fondaparinux. The strips 
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were sealed with adhesive tape and incubated at 37°C for 18 hours. The reaction was 
measured upon the addition of 3 µL per well of WST-1 reagent (Roche) in 0.1 M NaOH at 
100 µl final volume per well. The strips were then re-sealed and incubated for 1 hour at 60° 
C in oven OV3 (Biometra). The absorbance was measured at 595 nM with Infinite M200 
microplate reader (Tecan Trading).  
2.4 Cell biology methods  
 Cell culture  
The cell lines used were cultured in the respective growth medium as displayed in 
Table 11. Generally, the cells were sub-cultured at 80-90% confluency, usually reached 
twice per week, via washing with Dulbecco's PBS-Ca2+ and Mg2+ free (PBS -/-) and short 
incubation (2-3 min) with 0.25% Trypsin-EDTA (Gibco), to enable cells detachment. 
Following incubation with Trypsin-EDTA, the cells were resuspended in fresh culture 
medium and the solution centrifuged at 1000 rpm for 5 min with Varifuge 3.0 (Heraeus). 
In the case of C3H10T1/2 mesenchymal cells, known for their high sensitivity to contact 
inhibition, sub-culturing at ~70% confluency was preferred, likewise the usage of cells at 
low passage numbers (< passage 7). The endothelial HUVECs were used only between 
passage 3 to 5 and sub-cultured at 80% confluency at a ratio of 2500-5000 cells/cm2 in T-
25/75 flasks (Thermo Fisher Scientific). For HUVECs detachment, PBS -/- was applied for 
washing steps and further incubation for 1 min with Trypsin/EDTA ratio of 0.04%/0.03%. 
(Promocell) to enable cell detachment. All cells were allowed to proliferate at 37 °C in a 
humidified 5% CO2 incubator (Heraus). 
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Table 11: Growth medium conditions for each cell line 
 Protein expression in HEK293 cells  
The Shh-N plasmid construct previously cloned (2.2.2) and verified by sequencing 
(2.2.5) was then transiently transfected into HEK293 cells to enable expression of lipids 
modified Shh-N protein secreted in the culture medium. At 24 hours prior transfection, 
HEK293 cells were seeded at a density of 3x106 cells/plate in a 100x20 mm culture dish 
(Corning) in DMEM culture medium supplemented with 10% FBS and 1% Pen/Strep. 
Afterward, the transfection was performed with Lipofectamine 3000 reagent (Invitrogen), 
following the manufacturer´s instructions. Transfection was performed for both Shh-N 
carrying vector and control pcDNA6/V5-His A empty plasmid, in order to obtain Shh-N 
conditioned medium (Shh-N CM) and control conditioned medium (control CM), 
respectively. In a first attempt, the supernatant was collected 72 hours after transfection. 
Next, for enabling both optimal purification and for cell-based applications, 24 hours after 
transfection, the culture medium was exchanged from 10% FBS to reduced serum 
conditions (2% FBS) and cells further cultivated for 72 hours (96 hours post-transfection). 
The supernatant was then collected, centrifuged 2 times at 1000 rpm and sterile filtrated 
(0.22 µm). Protein expression was confirmed by SDS-page gel electrophoresis (2.3.2) and 
immunodetection (2.3.4). The conditioned medium was stored at 4°C and -20°C in case of 
longer storage or either directly used for purification proposes (2.3.1). 





Dulbecco's Modified Eagle's medium (DMEM) + 10% FBS and 1% 
Pen/ Step 
MIA-PaCa-2 DMEM +10% FBS, 2.5 % horse serum, 1% Pen/Strep 
ShhL2 
DMEM + 10% FBS, 1% Pen/ Step, 1% sodium pyruvate, 150 µg/mL 
zeocin and 400 µg/mL geneticine 
HUVECs 
Endothelial growth medium 2 Bulletkit (EGM2): 2% FBS, 
Hydrocortisone, hFGF2, VEGF, R3-IGF-1, Ascorbic Acid, hEGF, GA-
1000, Heparin. At manufacturer´s concentrations  
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 Alkaline phosphatase (ALP) activity assay 
For the assay, murine fibroblasts osteoblast precursors C3H10T1/2 cells were plated 
at the density of 2x104 cells/well (c/w) in 96-well plate. Cells were cultivated for 24 hours 
in DMEM supplemented with 10% FBS and 1% Pen/Strep to reach over-confluency. 
Afterward, the medium was switched to 2% FBS. Dilutions of Shh-N CM and control CM 
(2% FBS) in fresh culture medium (2% FBS) were tested for pathway activation at ratios 
ranging from 1:2 to 1:1000 CM/fresh DMEM. For inhibition studies the compounds tested 
dPGS, dPGTPs, Heparin and GANT61 were added to the 1:10 CM/DMEM ratio mixture 
at the reported concentrations, generally ranging between 3 nM to 10 µM. Treated cells 
were then allowed to grow for 72 hours. Afterward, the medium was removed by gentle 
aspiration and 50 µl per well of lysis buffer [100 mM Tris pH 9.5, 250 mM NaCl, 25 mM 
MgCl2, 1% Triton X-100 supplemented with cOmplete protease inhibitor (Roche)] was 
added. The plate was shaken with a rocker for 40 minutes and further stored overnight at -
20°C to help cell lysis via one freeze and thaw cycle. 25 µl of the cell lysate from each well 
was transferred into a new 96-well plate, equilibrated to room temperature and further 
mixed with 25 µl of pNPP substrate (Sigma-Aldrich). The plate was gently shaken to 
homogenize the solution and then incubated for 30 min at 37°C. Absorbance was measured 
at 405 nm using microplate reader Infinite M200 (Tecan Trading). 
 Luciferase reporter assay 
Shh light 2 (ShhL2) cells, a murine fibroblast NIH3T3 cell line stably co-transfected 
with GLI-responsive firefly luciferase reporter and a constitutive luficerase renilla 
expression vector, were applied for the reporter assay. ShhL2 cells were plated in a 96-well 
plate at the density of 6x104 c/w in complete culture medium (2.4.1) and reached over-
confluency after initial 24 hours of incubation. Dilutions of Shh-N CM and control CM 
(2% FBS) in fresh DMEM supplemented with 0,5% FBS were tested for pathway activation 
at ratios ranging from 1:2 to 1:1000 CM/fresh DMEM. Inhibitors were added to 
CM/DMEM 1:10 dilution ratio at the concentrations reported, which generally ranged 
between 3 nM to 10 µM. Cells were incubated for further 30 hours, then the medium was 
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carefully removed and the cells were treated with 30 µl per well of cell lysis solution 1X 
Lysis-Juice (PJK GmgH). The plate was shaken with a rocker for 40 minutes and further 
stored overnight at -20°C to help cell lysis via one freeze and thaw cycle. 20 µl aliquots of 
lysis solution from each well were collected and plated into a Nunc F96 MicroWell white 
plate (Thermo Fisher Scientific). Beetle-Juice reagent containing D-luciferin and ATP (PJK 
GmgH) was used to quantify the amount of firefly luciferase contained in the cell lysate 
upon automatic injection of the substrate at 1:2 (v/v) ratio lysate/reagent. The measurement 
was carried out with a Luminoskan Ascent microplate reader (Thermo Fisher Scientific) at 
an integration time of 5 sec and a delay of 2 sec. 
 Lactate dehydrogenase (LDH) assay 
Cell cytotoxicity via lactate dehydrogenase (LDH) assay was performed in the case 
of the cell line C3H10T1/2 and ShhL2, used in the biological Shh-pathway reporter assays. 
The method based on the measurement of lactate dehydrogenase (LDH) activity present in 
the culture supernatant, which is released consequentially to cell death and plasma-
membrane damage. The cells were seeded in DMEM culture medium (supplemented with 
2% FBS for C3H10T1/2 and 0,5% FBS for ShhL2 cells) at the density of 5x103 c/w in a 
96-well plate and allowed to adhere after overnight incubation. Afterward, inhibitors 
(dPGTPs, dPGS, GANT61, and Heparin) at the reported concentrations were added to the 
cells, while 1% Triton-X100 was used for high control to induce cells death and complete 
LDH release. The LDH activity assay (Takara) was performed after 24 and 48 hours of 
incubation with the inhibitors and controls, following the manufacturer’s instruction. 
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 Detection of Shh-N protein in cells supernatant  
For the quantification of Shh-N released in the cell culture medium, the pancreatic 
cancer cells PANC1 and Mia-PaCa-2, the breast carcinoma cells MCF-7, lung 
adenocarcinoma A549 cells, the human embryonic kidney cells HEK293 and murine 
mesenchymal cells C3H10T1/2 were cultivated to confluence in a 100x20 mm culture dish 
(Corning) with the appropriate medium (2.4.1). Cell supernatant was then collected, 
centrifuged twice (1000 rpm), sterile filtered (0.22 µm) and stored at 4°C until use. 
The amount of Shh-N released by each cell line was measured by human Shh-N ELISA kit 
(R&D system), following the manufacturer´s instructions.  
 Endpoint measurement (ATP quantification) of cells proliferation  
The endpoint proliferation assay was performed with CellTiter-Glo luminescent 
assay (Promega). The assay bases on the measurement via luminescence reaction of cellular 
ATP, which corresponds to the quantity of metabolically active cells. The optimal number 
of cells per well to seed in order to maintain the cells in the log phase after 72 hours of 
treatment was determined for each specific cell line. In the specific, 2500 c/w for HEK293 
cells, 1250 c/w for A549 cells and 2000 c/w for PANC-1 cells were plated in a 96-well 
plate with reduced serum DMEM (2%FBS) and allowed to adhere overnight. 
Subsequentially, the cells were treated with the compounds at the reported concentrations 
and incubated for a further 72 hours. Celltiter-Glo (Promega) was performed according to 
the manufacturer´s instructions. For HUVECs, the assay was applied to analyze the 
viability of the cells upon treatment with dPGS. In this case, 5000 c/w were plated in a 96 
well/plate with complete EGM2 culture medium (2.4.1) and allowed to adhere for initial 6 
hours of incubation. Afterward, dPGS was added at the reported concentrations and the 
viability of the cells was monitored after 72 hours.  
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 Real-time monitoring of cells proliferation  
Real-time cell monitoring was performed with IncuCyte (Sartorius). HEK293, 
PANC-1, and A549 cells were seeded at the same density as above reported for the endpoint 
assay. The cells were incubated in DMEM supplemented with 2% FBS for the initial 24 
hours, time upon which the treatment with reported concentrations of dPGS and dPGTPS 
started. The proliferation rate was measured in terms of increment in cell confluency 
monitored via Incucyte v2019A software. For a better comparison and to rule out minor 
errors due to differential cell numbers between wells, the confluency value at the time point 
before compound addition (24 hours after seeding) was normalized to value 1. Real-time 
cell monitoring was performed for a total of 100 hours (76 hours after treatment).  
 Cellular spheroids formation  
Spheroids were obtained via plating cells into Cellcarrier spheroids ultra-low 
attachment (ULA) 96-well microplates (PerkinElmer) in DMEM (2% FBS). To enable cell 
aggregation the plates were centrifuged at 1000 rpm for 10 min in a Megafuge 2.0 (Heraeus) 
directly after cells seeding. The plates were then immediately incubated. Following the 
protocol described by Friedrich et al. [269] spheroids were formed that reached after 4 days 
of incubation a diameter of around 400 µm. The spheroid's morphology was monitored via 
microscopic observation with Inverted microscope Axio Observer Z1 (Carl Zeiss). Bright-
field pictures (4x magnification) were collected for the spheroids at each time point. The 
bright-field images were then analyzed via AnaSP [265], an open-source program that 
enables automatic extraction of the main morphological parameters (such as diameter, 
volume, area, and sphericity) from the bright-field images of the spheroids. The method of 
evaluation for the different parameters finds comprehensive explanations in the related 
article [265]. After optimization of initial cells seeding number, 500 c/w for PANC-1, 1000 
c/w for A549 and 125-250 c/w for HEK293 cells were seeded in order to obtain macro-
spheroids that reached by day 4th of incubation a diameter of ~400 µm. On day 4th of 
incubation, the treatment with dPGS and dPGTPS started. The medium was refreshed every 
2-3 days via carefully exchanging 50% of the volume (=100µl) with the use of a 
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multichannel (8 channels) pipette. For monitoring the effect of the treatment, the 
differential volume growth of control untreated compared to treatment at different time 
points were evaluated. Following the protocol of Friedrich et al. [269] the spheroid's growth 
was monitored up to 5-times increase of the initial volume. This condition was applicable 
in case of HEK293 and PANC-1 cells. For A549, the cells showed a slow growth rate and 
were monitored for 15 days upon seeding without reaching 5-times initial volume. For 
calculation of percentage volume decrease, the growth rate of spheroids was firstly 
calculated via subtracting the spheroids volume measured at day 4 (Vday4) to the time point 
of the observation (Vdayx). Following, the growth rate of treated spheroids was divided by 
the growth rate of untreated ones and multiplied to 100, which gave the percentage growth 
rate normalized to control untreated (100%). The percentage growth reduction was then 
calculated subtracting 100 to the percentage normalized growth rate.  
 Spheroids cytotoxicity analysis  
Spheroids were formed and treated as previously described (2.4.9). After 72 hours 
of incubation upon treatment, each spheroid in 100 µl volume was transferred with the help 
of 1 mL tip (ends cut) to a Nunc white 96-well plate (Thermofisher). Cytotoxicity test was 
performed via Celltiter-Glo3D kit (Promega), following the manufacturer´s instructions.  
 HUVECs angiogenic growth-factors-dependent proliferation  
HUVECs, cultured between passage 3 to 6, were seeded at a density of 2x103 c/w 
in a 96-well plate in EBM-2 endothelial basal medium supplemented only with 2% FBS 
and GA-1000, at the manufacturer´s concentrations. Cells were let adhere for initial 6 hours 
of incubation. Afterward, VEGF, FGF1, and FGF2 diluted in EBM-2 (2% FBS, GA-1000) 
at increasing concentrations ranging between 0.01 to 1000 ng/ml were added to the cells at 
200 µl final volume. For dPGS/heparin inhibition studies, fixed concentrations of cytokines 
( 3 ng/ml of FGF2 and 50 ng/ml of either FGF1 and VEGF) were mixed with increasing 
concentrations of inhibitor ranging between 5 to 50 µM in 200 µl final volume and initially 
incubated for 5 min prior adding it to the cells. After 72 hours of incubation, the 
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proliferation was measured following the addition of 20 µl per well of Celltiter AQueous 
one solution MTS proliferation assay (Promega) directly to the cell culture medium. 
The reagent contains a tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, MTS] combined with an 
electron coupling phenazine ethosulfate (PES), and enables to estimate the number of 
metabolically active cells proportionally to the mitochondrial conversion of MTS to 
formazan. Cells were incubated in the presence of MTS reagent for further 2 hours. 
The absorbance was recorded at 490 nm with Infinite M200 microplate reader (Tecan 
Trading).  
 HUVECs tubes formation assay 
For tubes formation assay, HUVECs cultured always between passage 3 to 6, were 
sub-cultured one day before the experiment in a T25 flask (Corning) at a density of 1x104 
cells/cm2, in order to reach 70% confluency after 24 hours incubation. Cultrex reduced 
growth factor basement membrane (BME) matrix (Trevigen) was allowed to thaw 
overnight in an ice bucket at 4 °C, further aliquoted on ice and stored at -20°C. Prior to the 
experiments, to prevent matrix jellification, which rapidly takes place above 8°C, all 
consumables required, such as tips and µ-slides Ibitreat (Ibidi), were let cool down to -20°C 
for minimum 30 min. 100 µl frozen BME matrix was rapidly thawed on ice and 10 µl was 
carefully added to each well of a µ-slide, also located on ice. The slide was gently tapped 
at the sides to ensure uniform distribution. The BME was let polymerize at 37°C for 40 
min. HUVECs were diluted to a final volume of 70 µl per well at the optimal density of 
9x103 c/w (µ-slide) in EGM-2 containing all supplements excluded heparin in presence or 
absence of dPGS (5, 10 and 50 µM). The mixture of cells and inhibitors were added to each 
well of a BME-coated-µ-slide and incubated at 37°C. After 5-, 8- and 20-hours a phase-
contrast picture (4x magnification) was collected for each well with inverted microscope 
Zeiss Axio Observer z-1 (Zeiss). Picture analysis was performed via ImageJ tool 
Angiogenesis analyzer. Tube formation efficiency was evaluated considering three 
parameters: total tube lengths (pixel), number of nodes and total meshes area (pixel) per 
field.  
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2.5 Statistical analysis  
The Kruskal-Wallis non-parametric test followed by Dunn´s post-test was applied 
to compare differential treatments to control untreated, in case of data that did not follow a 
normal distribution. Confidence interval percentage was set to 95% and p-value ≤ 0.05 
considered significant. Normally distributed data were validated by the quantile-quantile 
(Q-Q) plot and by the D’Agostino Pearson normality test. Assuming normal distribution, 
one-way ANOVA followed by Dunnett’s post hoc test was applied.  




3.1 Dendritic polyglycerol sulfates as potential Shh pathway inhibitors  
 Shh-N protein expression and purification 
The active fragment of Shh protein coding for Shh-N terminus was cloned into a 
plasmid vector pcDNA6/V5 His-A enabling eukaryotic expression. Furthermore, the DNA 
was fused in-frame to a poly-histidine tag for further purification purposes. The eukaryotic 
expression system was chosen as it enabled to express the dually lipidated (cholesterol and 
palmitoyl modified) active Shh-N protein. The transient transfection of HEK293 cells was 
achieved by lipofection. Given the lipid modifications, Shh anchors and multimerizes at the 
cell membrane level and, from there, it is released into the extracellular space. Therefore, 
it was expected to detect the protein in the cell culture medium of the transfected HEK293 
cells, also called Shh-N conditioned medium (Shh CM). As a control, a parallel expression 
of the plasmid vector without insert was performed and the respective supernatant named 
control conditioned medium (Control CM). Transfection was initially performed in the 
presence of 10% (FBS) and 2% FBS, collected after 72 hours and 96 hours post-
transfection, respectively (see 2.4.2 for details). The secretion of recombinant Shh-N was 
monitored via Coomassie protein staining (Figure 12a) and immunodetection using a 
polyclonal antibody against Shh-N protein (Figure 12b). As predicted, the Shh-N protein 
was released in the culture medium and migrated in a three bands pattern with a molecular 
mass of about 19 kDa, which agrees with the expected molecular mass of the mature Shh-
N. The absence of protein was confirmed for the control supernatant derived from 









Figure 12: Shh-N protein expression in HEK293 cells. Detection via a) Coomassie protein staining and b) 
Western blot immunodetection. Transient expression of Shh-N protein and control empty vector in 10% FBS 
containing cell medium collected at 72 hours after transfection and expression of Shh-N protein in 2% FBS 
containing culture medium collected after 72 hours from medium switch (96 hours post-transfection).  
3.1.1.1 Shh-N protein purification 
The presence of the polyhistidine-tag allowed for the purification of the 
recombinant protein via Ni-NTA affinity chromatography (Figure 13). Furthermore, a 
reduction of FBS content from 10 (Figure 13a) to 2% (Figure 13c) during expression 
resulted in increased purity of the protein after purification. The silver gel staining in Figure 
13c supports the purity of the eluted and concentrated sample (lane 8) with predominant 
bands corresponding to 19 kDa-migrating Shh-N, whereas only a faint band could be 
detected corresponding to the molecular mass of FBS (~65 kDa).  
 
 








Figure 13: Shh-N protein detection and purification. a) Coomassie protein staining and b) Western blot 
immunodetection for Ni-NTA purification of Shh CM (10% FBS). M, marker; Flow-through; Wash; Eluted 
fractions (1-5); Final elution (column wash). c) Silver gel protein staining for Shh-N purification from Shh CM 
(2 % FBS) via Ni-NTA chromatography. 1, Shh-N CM input; 2, Flow-through; 3-7, Elution fractions; 8, Eluted 
fractions after PD10 column desalting and concentrated via Amicon-filter.  
 Surface Plasmon Resonance (SPR) affinity measurement for Shh-N 
to dendritic polyglycerol sulfates 
The binding affinity of the Shh-N protein towards both dendritic polyglycerol 
sulfate structures dPGS and the shell cleavable variant dPGTPS was studied via surface 
plasmon resonance (SPR). For the binding assay, the sulfated compounds were synthetized 
as biotinylated ligands and further immobilized on a streptavidin (SA) precoated SPR-
sensor chip. Increasing concentrations of Shh-N were injected and the interaction recorded 
via single-cycle kinetics experiments (SCK). The SPR sensorgrams describing Shh-N 
binding are shown in Figure 14. Binding constants are given as association constant (ka), 
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dissociation constant (kd) and equilibrium dissociation constant (KD) and derive from the 
fit assuming the 1:1 Langmuir interaction model. For both macromolecules, a similar 
binding behavior was observed, with KD values in nM range. Specifically, the polymer 




Figure 14: Single-cycle kinetics (SCK) evaluation of Shh-N-dPGS/dPGTPS interaction. Representative 
sensorgram of the Resonance Units (RU) response against time during SCK experiment performed via injecting 
five increasing concentrations of Shh-N over either dPGS (top) or dPGTPS (bottom) functionalized SPR sensor 
chip. The fitting was obtained by using a 1:1 Langmuir binding model. The kinetic constants (ka, kd, KD ±SE) 
are reported beside the sensorgram. For dPGS interaction evaluation, Shh-N was injected at concentrations of 
125, 250, 500, 1000 and 2000 nM, whereas for dPGTPS was injected at concentrations of 25, 74, 222, 667 and 
2000 nM.  
ka (M-1s-1) = (8.933±0.08) E+03 
kd (s-1) = (3.36±0.1) E-04 
KD = (3.76±0.1) E-08 
ka (M-1s-1) = (3.41±0.02) E+04 
kd (s-1) = (3.03±0.07) E-04 
KD = (8.87±0.02) E-08 
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 In vitro quantitative analysis of Shh-signaling pathway activation in 
cell-based assays  
To study the Shh-signaling pathway, investigations were performed in two distinct 
reporter cell lines. In the first place, experiments were carried out with the C3H10T1/2 cell 
line, a fibroblast pre-osteoblast cell line that expresses as osteogenesis marker, the alkaline 
phosphatase (ALP) enzyme, upon Shh-pathway activation. Second, an NIH-3T3 reporter 
cell line stably transfected with a GLI-dependent firefly luciferase reporter, named Shh 
Light2 (ShhL2) cells, was applied. In this cell-based assay, the luciferase expression is 
specifically led by the activation of GLI-transcription factors as a result of Shh-pathway 
activation. GLI translocation to the nucleus and subsequent binding to an 8xGLI binding 
factor cassette activates the promoter controlling luciferase expression. The luciferase is 
ultimately measured, upon reaction with a specific substrate, as light signal emission.  
3.1.3.1 Conditions optimization for Shh-signaling pathway activation  
The activation of the Shh-pathway was first tested and optimized for both cell-based 
assays (Figure 15).  
a) 




Figure 15: Activation of Shh-pathway in luciferase and ALP reporter cell-based assays. a) Activation of 
Shh-pathway in the C3H10T1/2-ALP reporter cell line. Reported dilution ratios of either Shh CM or control 
CM in fresh DMEM cell culture medium were added to the cells and incubate for 72 hours. ALP was measured 
via colorimetric reaction read at 405 nm absorbance. b) Shh-pathway activation in ShhL2 luciferase reporter 
cell line. Reported dilution ratios of either Shh CM or control CM in cell culture medium were added to the 
cells and incubated for 30 hours. Luciferase activity was measured after reaction with firefly luciferase and 
expressed as normalized RLU emitted. For both assays, the results are expressed as normalized to untreated 
control (DMEM control). Bars represent the mean of n=4 independent experiments each performed in 
quadruplicates ± SEM. 
Shh-pathway was stimulated by treating the cells with dilutions of either Shh CM 
or control CM in fresh culture medium. For further studies and for both assays the 1:10 
dilution ratio of Shh-N conditioned medium was chosen as enabled a reasonable pathway 
activation. The absence of unspecific activation was observed in the case of treatment with 
control CM and with DMEM growth medium.  
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3.1.3.2 Inhibition of Shh-pathway in ALP- reporter cell line  
 At first, the capability of dPGS and dPGTPS to down-regulate Shh-pathway was 
tested in the ALP-reporter cell-based assay. The inhibitory activity of the dendritic 
polyglycerol sulfates was compared to heparin and the specific inhibitor of GLI 
transcription factor GANT61 (Figure 16).  
Figure 16: Inhibition of Shh-pathway in C3H10T1/2-ALP reporter cell line by dPGS, dPGTPS and 
controls heparin and GANT61.  The pathway was stimulated with Shh CM: DMEM at a 1:10 ratio. Increasing 
concentrations of dPGS, heparin, GANT61 (ranging between 30 nM to 10 µM) and dPGTPS (ranging between 
3 nM to 1 µM) were mixed with the stimulation medium and added to the cells. ALP production was measured 
after 72 hours of incubation. Both dPGS and dPGTPS showed high inhibitory potential, slightly higher than 
heparin and 100-fold stronger when compared to GANT61. The results are expressed as percentage normalized 
to Shh-pathway activation treatment set to 100% activity. Bars represent the mean of n>4 independent 
experiments each performed in quadruplicates ± SEM. 
In this case, both dPGS and dPGTPS showed a comparable strong pathway 
inhibitory capacity with IC50 values of 81 and 72 nM, respectively. The natural polysulfate 
heparin showed indeed an IC50 of 330 nM and GANT61 a higher IC50 value of 8.8 µM. 
In Figure 17 are reported the controls experiments showing the absence of 
unspecific effects potentially derived from control CM in combination with the inhibitors.   
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Figure 17: Control experiments: inhibition of Shh-pathway in C3H10T1/2-ALP reporter cell line by 
dPGS, dPGTPS and controls heparin and GANT61. The pathway was stimulated with either control CM 
or Shh CM diluted at a 1:10 ratio in fresh DMEM culture medium. Increasing concentrations of dPGS, heparin, 
GANT61 (ranging between 30 nM to 10 µM) and dPGTPS (ranging between 3 nM to 1 µM) were mixed with 
the stimulation medium and added to the cells. For GANT61 a control with DMSO (0,2 %) was performed. 
ALP production was measured after 72 hours of incubation. The results are expressed as percentage normalized 
to Shh-pathway activation treatment, set to 100% activity. Bars represent the mean of n>4 independent 
experiments each performed in quadruplicates ± SEM.  
To confirm that the inhibition of Shh-pathway did not correspond to a side effect of 
the compound cytotoxicity, cell viability studies were performed by measuring the amount 
of the released cellular cytosolic enzyme lactate dehydrogenases (LDH) (Figure 18) in 
response to concentration-dependent treatments. For comparisons and calculations, in the 
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positive control, the cells are treated with 1% Triton-X for the whole duration of the 
experiment, in order to ensure complete cell death. The cytotoxicity assays were performed 
after 24 and 48 hours. The results confirmed the absence of cytotoxic effects, with only a 
reduction of the viability below 10% detected after 48 hours incubation.  
 
Figure 18: LDH-based cytotoxicity assay for C3H10T1/2 cells after 24- and 48-hours treatment with 
dPGS, dPGTPS and controls heparin and GANT61. Cells were seeded in a 96-well plate at the density of 
5.000 c/w and treated after 24 hours incubation with reported concentrations of dPGS, dPGTPS, heparin, and 
GANT61. For the positive control, 1% Triton-X was used to ensure complete cell death. Negative control 
corresponds to untreated cells. For all treatments, no cytotoxicity was observed. Cytotoxicity is expressed in 
percentage and calculated as reported in the material and method section 2.4.5. Bars represent the mean of n>3 
independent experiments each performed in triplicate ± SD.  
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3.1.3.3 Inhibition of Shh-pathway in luciferase-reporter cell line  
Afterward, the inhibitory efficiency of the compounds was evaluated in the 
luciferase reporter cell line ShhL2 (Figure 19). In agreement with the ALP measurement, 
dPGTPS and GANT61 showed activities with respective IC50 values of 111 nM and 1.2 
µM. However, surprisingly, the treatment with dPGS resulted in a remarkably reduced 
inhibition in comparison to the ALP measurements, with a measured IC50 of 6.5 µM, 80-
fold higher than the value measured in the ALP-based assay. An even more evident 
reduction was noticed in the case of heparin, where apparently a slight dose-dependent 
inhibition can be observed, which however led only to a 15% pathway inhibition at the 
highest concentration tested (10 µM), impeding thus IC50 determination. 
Figure 19: Inhibition of Shh-pathway in ShhL2 luciferase reporter cell line by dPGS, dPGTPS and 
controls heparin and GANT61. The pathway was stimulated with Shh CM: DMEM at a 1:10 ratio. Increasing 
concentrations of dPGS, heparin, GANT61 (ranging between 30 nM to 10 µM) and dPGTPS (ranging between 
3 nM to 1 µM) were mixed with the stimulation medium and added to the cells. Luciferase expression was 
measured after 30 hours of incubation. dPGTPS and GANT61 inhibit Shh-pathway, in agreement with ALP 
assay. Contrary, dPGS, and heparin showed remarkably reduced inhibitory capacity. The results are expressed 
as percentage normalized to Shh-pathway activation treatment set to 100% activity. Bars represent the mean 
of n>4 independent experiments each performed in quadruplicates ± SEM.  
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In Figure 20 are reported the control experiments showing the absence of unspecific 
pathway inhibition.  
Figure 20: Control experiments: inhibition of Shh-pathway in ShhL2 luciferase reporter cell line by 
dPGS, dPGTPS and controls heparin and GANT61. The pathway was stimulated with either control CM 
or Shh CM diluted at a 1:10 ratio in fresh DMEM culture medium. Increasing concentrations of dPGS, heparin, 
GANT61 (ranging between 30 nM to 10 µM) and dPGTPS (ranging between 3 nM to 1 µM) were mixed with 
the stimulation medium and added to the cells. For GANT61 a control with DMSO (0,2 %) was performed. 
Luciferase expression was measured after 30 hours of incubation. The results are expressed as percentage 
normalized to Shh-pathway activation treatment, set to 100% activity. Bars represent the mean of n>4 
independent experiments each performed in quadruplicates ± SEM.  
To evaluate the cytotoxicity of the compounds, cell viability studies via LDH 
cytotoxicity assay were performed for ShhL2 cells (Figure 21).  
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Figure 21: LDH-based cytotoxicity assay for ShhL2 cells after 24- and 48-hours treatment with dPGS, 
dPGTPS and controls heparin and GANT61. 24 hours after seeding the cells in a 96 well/plate at the density 
of 5.000 c/w and treated with reported concentrations of dPGS, dPGTPS, heparin, and GANT61 in DMEM 
0,5% FBS. For the positive control, cells were treated with 1% Triton X, to ensure complete cell death. 
Negative control corresponds to untreated cells. For all treatments, no cytotoxicity was observed. Cytotoxicity 
is expressed in percentage and calculated as reported in material and method (2.4.5). Bars represent the mean 
of n>3 independent experiments each performed in triplicate ± SD.  
Measurements were carried out at 24 and 48 hours of cell incubation with the tested 
compounds and controls. The results confirmed the absence of cytotoxic effects at 24 hours 
incubation with ≤10% viability reduction at the highest concentrations. However, at 48 
hours an increase in cytotoxicity was observed for dPGS and dPGTPS with ≤ 20% viability 
reduction at concentrations above 300 nM. Despite the viability measurements were carried 
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out at 24- 48-hours of incubation, luciferase assay was performed always after 30 hours 
incubation with the compounds. Therefore, a reduced influence of the compound’s toxicity 
on the reduction of Shh pathway activation is expected. 
 dPGS and dPGTPS effect on autocrine Shh-pathway- mediated 
proliferation  
Shh-signaling pathway in cancer operates via diverse models of activation (1.3.3). 
Autocrine pathway activation depends on tumoral cells up-regulation of ligand expression, 
which supports the cancer cells self-operating signaling loop activation and perpetuation. 
Thus, cancer cells that are secreting Shh protein, are expected to possibly respond to the 
produced ligand and activate Shh-autocrine signaling to support their proliferation and 
metastasis.  
3.1.4.1 Shh-N expression and release in cancer and non-malignant cells  
At first was performed a screening of cells expressing Shh protein and secreting it 
in the cell culture medium, as an earliest indication for potential Shh-pathway activation. 
In addition, the selection of the specific cancer cell lines based on literature information 
that confirms the expression of the Shh-pathway ligand and cascade components for the 
cell lines included in the study. To quantify the ligand expression and secretion capacity of 
each cell line, cells were cultivated to confluence and the culture supernatant analyzed via 
a sandwich ELISA (2.4.6). The results are reported in Figure 22. The assay confirmed that 
the cancer cells included in the screening as pancreatic cancer cells PANC1 and MiaPaCa-
2, breast carcinoma cells MCF-7 and lung adenocarcinoma A549 cells, differentially 
express and secrete Shh-N in the cell culture medium. Moreover, a significantly reduced 
release of Shh-N was confirmed for the control cell lines, as visible for the human 
embryonic kidney cells HEK293 and murine mesenchymal stem cells C3H10T1/2. 
Those, as non-tumorigenic cells, are expected to show reduced or absent expression of Shh 
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ligand, although they are known to present the signaling machinery to respond to Shh-
ligand dependent signal activation.  
Figure 22: ELISA quantification of Shh-N secretion in cell culture medium in carcinogenic and non-
carcinogenic cell lines. Cells were cultivated to confluence and cells supernatant was used for Shh-N amount 
quantification via sandwich ELISA. Differential Shh-N expression and secretion was confirmed by 
tumorigenic cell lines, whereas a significantly reduced amount of ligand was detected in control non-
tumorigenic cells. Bars represent the mean of n=2 independent experiments each performed in triplicate ± SD.  
3.1.4.2 dPGTPS and dPGS-dependent anti-proliferative activity in 2D cell 
culture-based assays 
The proliferation of A549 and PANC1 cells is known to be affected by Shh-
signaling pathway. Furthermore, the above described ELISA assay confirmed the 
production and release of the ligand in both cell lines. Given the differential amount of Shh 
expressed by the individual cell lines, low-level (A549, CCL226, HEK293) and high-level 
(PANC-1, MCF-7) ligand producers cells could be discriminated. To assess if a differential 
Shh ligand-concentration might influence the anti-proliferative effect of potential Shh-
pathway inhibitor, the cell lines A549 and PANC-1 were selected, whereas the HEK293 
cells were included as a control cell line. A proliferation/viability endpoint method was 
compared to a real-time live-cell analysis method. Figure 23 displays the influence of 
dPGS and dPGTPS on the proliferation of lung adenocarcinoma A549 cells.  
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Figure 23: A549 cell proliferation studies via endpoint and real-time measurements. a-c): Endpoint 
evaluation of dPGS (a) and dPGTPS (c) influence on A549 cells proliferation. Results are normalized to 
untreated control set to 100%. Points represent the mean of n≥2 independent experiments each performed in 
quadruplicate ± SEM. b-d): live-cells analysis of the proliferation of A549 cells upon treatment with dPGS (b) 
and dPGTPS (d). Results show the change in cell confluence over time upon treatment at 24 hours after cells 
seeding (t=24h). Results are expressed as normalized to t=24h set to 1. Points represent the mean for each 
condition performed in quadruplicates ±SD. 
A549 cells, are low-level Shh ligand producers but known to depend also on Shh-
signaling for their proliferation. Surprisingly, dPGS had no effect in terms of reduction of 
cell proliferation both in endpoint measurement (Figure 23a) and in the real-time analysis 
(Figure 23b); not even at the highest concentration (30 µM). In contrast, the sulfated 
compound dPGTPS showed a concentration-dependent reduction of proliferation, with an 
IC50 of 2.27 µM, when quantified via endpoint measurements (Figure 23c). 
The result obtained from the endpoint measurement additionally corresponds to the real-
time proliferation analysis via Incucyte (Figure 23d), where at 100 hours after seeding, 
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Based on high Shh ligand expression, the pancreatic carcinoma PANC-1 cells were 
further tested (Figure 24).  
Figure 24: PANC1-1 cell proliferation studies via endpoint and real-time measurements. a-c): Endpoint 
evaluation of dPGS (a) and dPGTPS (c) influence on PANC-1 cells proliferation. Results are normalized to 
untreated control set to 100%. Points represent the mean of n=3 independent experiments each performed in 
quadruplicate ± SEM. b-d): live-cells analysis of the proliferation of PANC-1 cells upon treatment with dPGS 
(b) and dPGTPS (d). Results show the change in cell confluence over time upon treatment at 24 hours after 
cells seeding (t=24h). Results are expressed as normalized to t=24h set to 1. Points represent the mean for each 
condition performed in quadruplicates ±SD. 
In the case of dPGS, despite the endpoint measurement (Figure 24a) showed a 
slight concentration-dependent decrease of proliferation, with ≤20% reduction of 
proliferation at 30 µM, the real-time monitoring (Figure 24b) exhibited an absence of 
substantial effect dPGS-dependent. In contrast, dPGTPS showed again a decrease in cells 
proliferation. Interestingly, for PANC-1 cells the anti-proliferative effect of dPGTPS was 
lower than in comparison to the effect observed for A549 cells. For the endpoint 
measurement (Figure 24b), dPGTPS, in a dose-dependent manner, affected cell 
proliferation resulting in a 20% reduction at 10 µM concentration, a value which drastically 
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15 µM was calculated. Comparable values were obtained for real-time monitoring assays 
(Figure 24b), for which an IC50 of 11 µM was calculated.  
The results showed the absence of an anti-proliferative effect for dPGS in both 
cancer cell lines under study. In contrast, dPGTPS displayed a dose-dependent inhibiting 
effect on cancer cell proliferation. The result at this point might suggest a potential anti-
tumorigenic capacity for the dPGTPS. To test this hypothesis, the effect of the polysulfates 
was evaluated on non-carcinogenic cell line HEK293 cells (Figure 25). 
Figure 25: HEK293 cell proliferation studies via endpoint and real-time measurements. a-c: Endpoint 
evaluation of dPGS (a) and dPGTPS (c) influence on HEK293 cells proliferation. Results are normalized to 
untreated control set to 100%. Points represent the mean of n=3 independent experiments each performed in 
quadruplicate ± SEM. b-d: live-cells analysis of the proliferation of HEK293 cells upon treatment with dPGS 
(b) and dPGTPS (d). Results show the change in cell confluence over time upon treatment at 24 hours after 
cells seeding (t=24h). Results are expressed as normalized to the value at t=24h set to 1. Points represent the 
mean for each condition performed in quadruplicates ±SD.  
Despite the fact that for dPGS neither in the endpoint measurement (Figure 25a) 
nor in the real-time analysis system (Figure 25b) an anti-proliferative effect was observed, 
dPGTPS induced indeed a decrease of the cells proliferation in a concentration-dependent 
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the endpoint method (Figure 25c) and an IC50 of 10.7 µM in the live-cell analysis (Figure 
25d).  
3.1.4.3 Dendritic polyglycerol sulfates affect cellular growth in 3D-
spheroids model 
2D cell culture systems are able to generally represent the cells physiological 
conditions, but lack in recreating the real cellular environment, where ECM deposition by 
the cells, higher cell-to-cell, and cells-to-ECM contacts contribute in maintaining cell 
homeostasis, as well regulating cells response to drugs. Therefore, to better understand the 
effect of dPGS and the variant dPGTPS in a more physiological context, cell culture studies 
were performed in a 3D-cell system via the formation of cellular spheroids. Here, the 
cultivation of the cells occurs on an Ultra-Low Adherent (ULA)-coated surface to stimulate 
the formation of a single cellular aggregate, called spheroid. Given their compact assembly, 
the spheroids of ~400 µm diameter are considered to mimic more closely the in vivo 
microarchitecture of human solid tumors, as they develop a particular structural 
organization where three main cells layers can be distinguished: a proliferative external 
cells layer, a middle quiescent and an internal necrotic layer. Going from the external to the 
internal layer, hypoxia and catabolites accumulation increase, while the reduction of 
nutrients and metabolites takes place.  
In this study, the evaluation of the spheroids proliferation was assessed via 
monitoring changes in volume growth after treatment, which started at day 4 after cells 
seeding, and ended when the spheroids reached about 5-times the initial volume or at day 
15 (in case of slow-growing cells). For each cell line, the number of cells to be seeded in 
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• Lung adenocarcinoma A549 cells  
In the case of A549 cells, 1000 c/w were seeded in a 96-well plate and resulted after 
4 days incubation in spheroids of approximately 400 µm diameter (Figure 26).  
Figure 26: Cell number optimization for A549 spheroids. A549 cells were seeded in DMEM (2 % FBS) at 
reported cell densities per well in a ULA-96 well microplate. Images of single spheroids were collected at day 
4 of incubation and the diameter (µm) analyzed via image analysis AnaSP software. For the cell number 
optimization study, each condition was performed in sextuplicate Representative 10x magnification phase-
contrast images are shown. Scale bar = 100 µm. 
Figure 27 shows the effect of the polysulfates on A549 spheroids. Surprisingly, in 
contrast to the lack of anti-proliferative capacity found in 2D-cells culture, a clear reduction 
of A549 spheroids growth was observed. The decrease in cell growth followed an apparent 
dose-dependent manner, and at concentrations ≥30 nM led to complete inhibition of 
spheroids growth. The growth was followed for 15 days (11 days of treatment) without the 
cells reaching 5-fold increase of the initial volume, as A549 cells, in contrast to 2D 
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monolayer growth, showed relatively lower growth rate when cultured as spheroids. At the 
end point of the observation (day 15), dPGS at the concentration of 3 nM resulted in 41% 
growth decrease whereas the concentrations above showed ~91% growth reduction 
compared to control untreated (t=15 days) set to 100%. Specifically, 30 nM induced a 
reduction of 91%, 300 nM of 97%, 3 µM of 83% and 30 µM of 94%. To confirm that the 
observed effect did not correspond to eventual compound cytotoxicity a spheroid 
cytotoxicity test was performed after 72 hours upon treatment start (days 7 after seeding) 
(Figure 27b). No significant dPGS-dependent cytotoxic effect was measured at all 
concentrations tested. dPGS at 3 nM concentration resulted in 100% spheroids viability 
whereas higher concentrations caused a slight viability reduction which ranged between 
78% to 87% in comparison to the untreated control. 
 
 




Figure 27: Growth and cytotoxicity analysis of A549 cancer cells spheroids upon dPGS treatment over 
a period of 15 days. A549 cells were seeded at 1000 c/w density in a ULA-96 well microplate and cultivated 
until day 4, time upon which dPGS treatment began. a) Images of single spheroids were collected at different 
time points over 15 days incubation. Spheroids volume of control untreated and treated with increasing dPGS 
concentrations was analyzed via image analysis AnaSP software. Points represent the mean of n=3 independent 
experiments each performed in quadruplicate ±SEM. Statistical significance determined by Kruskal-Wallis test 
followed by Dunn´s post hoc test (Graphpad prism 5.03). *P<0.05, **P<0,01, *** P<0,001 vs untreated 
control. Some representative images (4x magnification bright field) of each condition at day 4 and at day 15 
are shown. Scale bar= 100 µm. b) Cytotoxicity was measured at 72 hours of treatment via Cell-titer Glo 3D 
viability assay. Bars represent the mean n=2 independent experiments each performed in quadruplicate ± SD. 
dPGS did not affect the viability of A549 spheroids. 
dPGTPS displayed the same trend but with reduced anti-proliferative activity on 
A549 spheroids (Figure 28a). After 3 days of treatment, no substantial difference in growth 
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volume upon dPGTPS treatment was measured. Additionally, during the whole 
observation, 3 nM did not influence the growth of the spheroids. For higher concentrations, 
a reduction in spheroids volume growth was detected, especially visible at day 12 of 
spheroids culture. However, the highest dPGTPS concentration used (30 µM) did not show 
constant correspondence to this trend and additionally resulted at day 15 in spheroids 
damage with evident cell loss; a condition that might reflect a toxic effect in case of longer 
drug exposure. At the end of the observation (day 15) the concentrations above 3 nM 
reduced the growth of spheroids of ~58%, compared to control untreated set to 100%. 
Specifically, 30 nM induced a reduction of 52%, 300 nM of 68%, 3 µM of 64% and 30 µM 
of 49%. The cytotoxicity analysis performed at 72 hours after treatment begin did not show 
any substantial toxic effect (Figure 28b). dPGTPS at all the concentrations tested resulted 
in ≥80% cells viability  
 




Figure 28: Growth and cytotoxicity analysis of A549 cancer cells spheroids upon dPGTPS treatment 
over a period of 15 days. A549 cells were seeded at 1000 c/w density in a ULA-96 well microplate and 
incubated for 4 days before dPGTPS treatment. a) Images of single spheroids were collected at different time 
points over 15 days incubation. Spheroids volume of control untreated and treated with increasing dPGS 
concentrations was analyzed via image analysis AnaSP software. Points represent the mean of n=3 independent 
experiments each performed in quadruplicate ±SEM. Statistical significance was determined by Kruskal-
Wallis test followed by Dunn´s post hoc test (Graphpad prism 5.03). **P<0,01 vs untreated control. Some 
representative images (4x magnification bright field) of each condition at day 4 and at day 15 are shown. Scale 
bar = 100 µm. b) Cytotoxicity was measured at 72 hours of treatment via Cell-titer Glo 3D viability assay. 
Bars represent the mean n=2 independent experiments each performed in quadruplicate ± SD. dPGTPS did not 
affect the viability of A549 spheroids.  
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• Pancreatic cancer PANC-1 cells 
The optimized number of PANC-1 cells to be seeded in order to obtain cellular 
spheroids of approximatively 400 µm diameter at day 4 was found to be 500 c/w (Figure 
29).  
 
Figure 29: Cell number optimization for PANC-1 spheroids. PANC-1 cells were seeded in DMEM (2 % 
FBS) at reported cell densities per well in a ULA-96 well microplate. Images of single spheroids were collected 
at day 4 of incubation and the diameter (µm) was analyzed via image analysis AnaSP software. For the cell 
number optimization study, each condition was performed in sextuplicate. Representative 5x magnification 
phase-contrast images are shown. Scale bar= 100 µm 
As observed for A549 cells, as well for the pancreatic cancer cells PANC-1, dPGS 
significantly reduce spheroids volume growth in a dose-dependent fashion (Figure 30a); 
even though in a reduced manner when compared to the lung adenocarcinoma cells 
spheroids.  
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Figure 30: Growth and cytotoxicity analysis of PANC-1 spheroids upon dPGS treatment over a period 
of 12 days. PANC-1 cells were seeded at a density of 500 c/w in a ULA-96 well microplate and incubated 4 
days before dPGS treatment. a) Images of single spheroids were collected at different time points over 12 days 
incubation. Spheroids volume of control untreated and treated with increasing concentrations of dPGS was 
analyzed via image analysis AnaSP software. Points represent the mean of n=3 independent experiments each 
performed in quadruplicate ±SEM. Statistical significance determined by Kruskal-Wallis test followed by 
Dunn´s post hoc test (Graphpad Prism 5.03) *P<0,05 vs untreated control. Some representative images (4x 
magnification bright field) of each condition at day 4 and at day 12 are shown. Scale bar = 100 µm. b) 
Cytotoxicity was measured after 72 hours of treatment via Cell-titer Glo 3D viability assay. Bars represent the 
mean n=2 independent experiments each performed in quadruplicate ± SD. dPGS did not affect the viability 
of PANC-1 spheroids 
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dPGS at the concentration of 300 nM did not influence spheroids growth, however, 
at the concentrations of 3 and 30 µM a clear reduction of the spheroids growth could be 
detected, starting already after 6 days of treatment (day 10), and remarkably after 8 days 
(day 12, end of the observation). On day 12, when the spheroids reached 5-fold of the initial 
volume and formed a visible necrotic core, a dPGS concentration-dependent volume 
reduction was measured. Specifically, upon the treatment with 300 nM, 3 and 30 µM dPGS, 
the spheroids displayed respectively 17, 37 and 46% volume reduction, compared to 
untreated control (t=day 12) set to 100%. Moreover, dPGS did not result toxic for PANC-
1 cells, as shown by the spheroid cytotoxicity test in Figure 30b.  
dPGTPS treatment showed indeed to not influence the growth of PANC-1 spheroids 
up to 3 µM, whereas 30 µM treatment resulted in visible spheroids disaggregation and cell 
loss, leading to 75% volume growth reduction compared to control untreated (t=day 12) set 
to 100% (Figure 31a). Moreover, a cytotoxic effect was confirmed by a toxicity test, where 
34% reduction viability was observed already after 72 treatment with 30 µM dPGTPS 
(untreated control set to 100%). The growth inhibitory effect of 30 µM might, therefore, 
correspond to a cytotoxic effect rather than an anti-proliferative functionality.  
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Figure 31: Growth and cytotoxicity analysis of PANC-1 spheroids upon dPGTPS treatment over a 
period of 12 days. PANC-1 cells seeded at a density of 500 c/w in a ULA-96 well microplate are cultivated 
until day 4, time upon which dPGTPS treatment began. a) Images of single spheroids were collected at different 
time points over 12 days incubation. Spheroids volume of control untreated and treated with increasing 
dPGTPS concentrations was analyzed via image analysis AnaSP software. Points represent the mean of n=2 
independent experiments each performed in quadruplicate ±SEM. Some representative 4x magnification 
bright-field images for each condition at day 4 and at day 12 are shown. Scale bar = 100 µm. b) Cytotoxicity 
was measured after 72 hours of treatment via Cell-titer Glo 3D viability assay. Bars represent the mean n=2 
independent experiments each performed in quadruplicate ± SD. dPGTPS at 30 µM concentration induces 
PANC-1 spheroids toxicity.  
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• Human embryonic kidney HEK293 cells  
The optimized initial number of HEK293 cells to be seeded in order to obtain 
spheroids of approximatively 400 µm diameter at day 4 was found to be 250 c/w (Figure 
32).  
 
Figure 32: Cell number optimization for HEK293 spheroids. HEK293 cells were seeded in DMEM (2 % 
FBS) at reported cell densities per well in a ULA-96 well microplate. Images of single spheroids were collected 
at day 4 of incubation and the diameter (µm) was analyzed via image analysis AnaSP software. For the cell 
number optimization study, each condition was performed in sextuplicate. Representative 5x magnification 
phase-contrast images are shown. Scale bar = 100 µm 
When HEK293 spheroids, which reached at day 4 a diameter of about 400 µm, were 
treated with dPGS at concentrations of 300 nM, 3 and 30 µM, a controversial effect was 
observed (Figure 33). At days 7, when a 3.7-fold increase of the initial volume was 
achieved and the spheroids reached 570 µm diameter, the treatment with dPGS caused 
apparent increase in volume, with the highest pick observed upon treatment with 3 µM 
dPGS, which visibly resulted in partial loss of integrity (Figure 33, day 7-dPGS 3 µM). 
Additionally, also 30 µM caused a modification of the shape of the spheroid, tending to a 
more ellipsoidal form. No effect was detected for control untreated cells.  




Figure 33: Growth analysis of HEK293 spheroids upon dPGS treatment over a period of 7 days. HEK293 
cells seeded at a density of 250 c/w in a ULA-96 wells microplate are cultivated until day 4, upon which dPGS 
treatment began. Images of single spheroids were collected at different time points over 7 days incubation. 
Spheroids volume of control untreated and treated with increasing dPGTPS concentrations was examined via 
image analysis AnaSP software. Points represent the mean of n=2 independent experiments each performed in 
quadruplicate ± SEM. Some representative 4x magnification bright-field images for each condition at day 4 
and at day 7 are shown. Diameter (µm) of control spheroids at day 4 and 7 is reported. Scale bar= 100 µm.  
To test if the effect of dPGS treatment might be dependent on the diameter of the 
spheroids, the number of seeded cells was reduced to 150 c/w (Figure 34).  
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Figure 34: Growth and cytotoxicity analysis of HEK293 (150 c/w) spheroids upon dPGS treatment over 
a period of 7 days. HEK293 cells were seeded at a density of 150 c/w in a ULA-96 well microplate and 
cultivated until day 4, time upon which dPGS treatment began. a) Images of single spheroids were collected at 
different time points over 7 days incubation. Spheroids volume of control untreated and treated with increasing 
dPGS concentrations was examined via image analysis AnaSP software. Points represent the mean of n=2 
independent experiments each performed in quadruplicate ± SEM. Some representative 4x magnification 
bright-field images for each condition on days 4, 7 and 11 are shown. On day 11, in the case of 30 µM treatment, 
the arrow indicates early signs of loss of spheroids integrity, whereas for 3 µM treatment a clear spheroid 
disaggregation can be observed. Diameter (µm) of the control untreated spheroids is reported. Scale bar = 100 
µm. b) Cytotoxicity was measured after 72 hours of treatment via Cell-titer Glo 3D viability assay. Bars 
represent the mean n=2 independent experiments each performed in quadruplicate ± SD. 
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In this case at day 4, the spheroids have grown to a diameter of <300 µm, which 
reached 500 µm at day 7. Additionally, after 7 days of incubation, a 4.5-fold increase in the 
initial volume was achieved. At this point, dPGS did not seem to affect the volume growth 
of the spheroids and to cause any toxic effect (Figure 34a-b). However, when monitored 
the same spheroids at a later time point (day 11), a spheroids loss of integrity upon dPGS 
treatment took place: spheroid disaggregation was noticed upon treatment with 3 µM, 
whereas initial loss of integrity was identified in 30 µM treated spheroids. The results agree 
with previous observations for the experiments performed at lower cell density (Figure 
33). To notice, that in the control untreated, the cells grew without any substantial changes 
in architecture.  
The same experiment was performed for dPGTPS (Figure 35). In this case, the 
untreated control cells at day 4 have a diameter of 250 µm and 427 µm at day 7, moreover 
at day 7, a 4.4-fold increase of the initial volume was achieved. Upon dPGTPS treatment 
at 30 µM concentrations, a 48% reduction in spheroids volume in comparison to control 
untreated set to 100% was measured. Additionally, the influence of dPGS on spheroids 
viability did not follow a concentration-dependent trend; 3 µM dPGTPS decreased 20 % 
the spheroids viability whereas other concentrations showed no influence. Following the 
treatment for a longer time, as when observing the spheroids after 10 days of incubation,  
hints of loss of spheroids integrity were displayed at 3 µM dPGTPS. At this time point, the 
spheroids reached a diameter of 650 µm.  




Figure 35: Growth and cytotoxicity analysis of HEK293 (150 c/w) spheroids upon dPGTPS treatment 
over a period of 7 days. HEK293 cells were seeded at a density of 150 c/w in a ULA-96 well microplate and 
cultivated until day 4, time upon which dPGS treatment began. a) Images of single spheroids were collected at 
different time points over 7 days incubation. Spheroids volume of control untreated and treated with increasing 
dPGTPS concentrations was examined via image analysis AnaSP software. Points represent the mean of one 
experiment performed in quadruplicate ± SD. Some representative 4x magnification bright-field images for 
each condition on days 4, 7 and 10 are shown. On day 10, in case of 3 µM treatment, the arrow indicates an 
early sign of loss of spheroids integrity. Diameter (µm) of the control untreated spheroids is reported. Scale 
bar= 100 µm. b) Cytotoxicity was measured after 72 hours of treatment via Cell-titer Glo 3D viability assay. 
Bars represent the mean one experiment performed in quadruplicate ± SD.  
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3.2 dPGS as a dual Heparanase and angiogenesis inhibitor 
While until this point the focus has been on Shh-signaling pathway, further chapters 
will be aiming to evaluate the anti-angiogenic potential of dPGS in relation to its capacity 
to interfere with heparanase enzyme activity and to inhibit the activity of relevant 
angiogenic growth factors.  
 dPGS-Heparanase affinity measurement via SPR  
To assess the inhibitory capacity of dPGS on heparanase activity, their binding 
affinity was firstly evaluated. In the assay, increasing concentrations of heparanase were 
injected over a SA chip during SCK experiments. The SPR sensorgram describing dPGS-
heparanase binding is reported in Figure 36, together with the binding constants ka, kd and 
KD derived from the fit assuming 1:1 Langmuir interaction model. dPGS and Heparanase 
showed a relatively strong affinity with a KD value of 3.11 nM. 
 
Figure 36: Single-cycle kinetics (SCK) for heparanase-dPGS interaction using SPR. Sensorgram of the 
Resonance Units (RU) response against time during SCK experiment upon injection of five ascending 
concentrations of heparanase (25, 50, 100, 200, 400 nM) on dPGS-coated sensor chip. The fit was obtained via 
using a 1:1 Langmuir binding model. The kinetic constants (ka, kd, KD ±SE) are reported in the table beside the 
sensorgram.  
ka (M-1s-1) = (5.85±0.01) E+04 
kd (s-1) = (1.82±0.04) E-04 
KD = (3.11±0.08) E-09 
  Results 
92 
 
 Heparanase enzymatic activity assay 
To evaluate whether the binding of dPGS to heparanase impacts on its catalytic 
activity, a heparanase activity assay was performed. The assay bases on heparanase 
cleavage of a homogenous substrate called fondaparinux, a fully synthetic methyl glycoside 
of the antithrombin III (ATIII)- activating pentasaccharide sequence of heparin. 
The quantification of the enzymatic activity is based on the reaction of water-soluble 
tetrazolium salt (WST-1) with the reducing disaccharides products of the fondaparinux 
cleavage by heparanase. As a first step, the assay was validated by performing complete 
digestion of fondaparinux via overnight incubation with 5 nM heparanase in 40 mM sodium 
acetate buffer (pH 5.0) at 37°C (2.3.6). The result of the digestion (Figure 37), which was 
carried out by using increasing nmoles of substrate fondaparinux, allowed for the 
identification of the correct amount of substrate to use for future activity experiments.  
In the specific, 5 nM of heparanase in the presence of 10 nmoles of fondaparinux 
(corresponding to 100 µM) resulted in a suitable degradation level. The experiment showed 
in Figure 37 confirmed also the specificity of the detected signal, based exclusively on the 
reducing sugars products of enzymatic degradation; for both fondaparinux and heparanase 
alone a signal at the baseline level was measured.  
Figure 37: Heparanase activity assay validation. Response absorbance at 585 nm (Arbitary Units-AU) 
following overnight complete digestion of increasing nmoles of fondaparinux (1, 2, 4, 6, 8 and 10 nmoles) 
incubated with 5 nM heparanase at 37 °C for 24 hours in 40 mM sodium acetate buffer (pH 5.0). The specificity 
of the assay is validated by the absence of differential response in the case of controls where fondaparinux or 
heparanase alone are included. Bars represent the mean of n=3 experiments ± SD. 
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3.2.2.1 Inhibition of heparanase enzymatic activity 
Heparanase inhibition studies were performed for dPGS (Figure 38a) and as 
controls, for heparin and suramin (Figure 38b), both well-known heparanase inhibitors.  
a) 
b) 
Figure 38: Inhibition of heparanase activity by dPGS, heparin, and Suramin measured by using 
Fondaparinux assay. a) dPGS-dependent inhibition of heparanase activity. Reported concentrations of dPGS 
ranging from 100 pM to 100 nM were mixed with 5 nM heparanase for 5 minutes prior the overnight incubation 
at 37°C in the presence of 100 µM fondaparinux. Controls for fondaparinux, heparanase, and dPGS are shown. 
Bars represent the mean of n=3 experiments each performed in triplicates ± SD. b) Nonlinear regression curve 
showing heparanase inhibition activity for dPGS, heparin, and Suramin. For heparin concentrations ranging 
between 300 pM and 100 nM were used whereas for Suramin the concentrations used ranged between 1 µM 
and 100 µM. Points represent the mean n=3 experiments each performed in triplicates  ± S.D. Results are 
expressed as percentage normalized to control untreated (maximal substrate degradation) set to 100%.  
The inhibitors were incubated in the presence of heparanase for 5 minutes prior to 
mixing with 100 µM fondaparinux and further incubation for 24 hours at 37°C.  
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Absence of unspecific signal derived from the degradation of inhibitors was confirmed, as 
shown in Figure 38a in the case of dPGS control. In Figure 38b is reported the nonlinear 
regression curve describing dPGS, heparin and suramin inhibition of heparanase activity. 
For dPGS and heparin, an almost identical IC50 was calculated, respectively 2.62 nM and 
2.67 nM, whereas for Suramin 4000 times higher IC50 (11.13 µM) was measured. 
 dPGS affinity to pro-angiogenic growth factors VEGF, FGF1, and 
FGF2 
The capacity of dPGS to bind to FGF1, FGF2, and VEGF and to potentially interfere 
with their activity was then investigated. Firstly, SPR binding assays were carried out via 
SCK experiments. The SPR sensorgram for FGF1, FGF2, and VEGF to dPGS are shown 
in Figure 39. Considering the KD values extrapolated from the kinetic analysis assuming 
1:1 Langmuir interaction model, all three growth factors displayed a good binding affinity 
to dPGS in the low nM range. In the specific for FGF1 a KD of 170 nM was calculated, for 
VEGF a KD of 5 nM and for FGF2 a KD of 25 nM. Interestingly, looking at the association 
and dissociation constants, VEGF presents a fast ka (106 M-1s-1) as well as a fast kd (10-2 s-
1), which might describe a temporary shorter binding with consequently a reduced efficacy 
during treatment. For FGF1 seems indeed only dissociation to be fast (10-2 s-1), which still 
could affect the target binding efficacy. Indeed, FGF2 displays a good association rate (104 
M-1s-1) and relatively slow kd (10-4 s-1) suggesting that, in this case, the binding might be 
stable for a longer time and therapeutically more efficient.  





ka (M-1s-1) = (2.6±0.15) E+04 
kd (s-1) = (4.38±0.09) E-03 
KD = (1.7±0.05) E-07 
ka (M-1s-1) = (1.2±0.02) E+04 
kd (s-1) = (3.1±0.09) E-04 
KD = (2.5±0.08) E-08 




Figure 39: Single-cycle kinetics (SCK) for angiogenic growth factors-dPGS interaction using SPR. 
Sensorgrams of the RU response against time performed with the five increasing concentrations of growth 
factors injected as analytes over a dPGS-coated SA chip in SCK experiments. Concentrations applied: FGF1: 
21.9, 43.8, 87.5, 175, 350 nM ; FGF2: 12.3, 37, 111, 333, 1000 nM; VEGF: 0.391, 1.56, 6.25, 25, 100 nM. The 
fit was obtained by using a 1:1 Langmuir binding model. The kinetic constants ka, kd and KD±SE derived from 
the fit are reported in the tables beneath the sensorgram.  
 dPGS-inhibition of growth factors induced HUVECs proliferation 
Aim of this study was to determine whether the binding of dPGS to the growth 
factors might also downregulate their activity, for example by impeding their binding to 
their receptor or, alternatively, antagonizing with HS for their storage at the ECM level. 
Therefore, growth factors activity assays were performed via studying the capacity of each 
singular factor to induce the proliferation of human umbilical vein endothelial cells 
(HUVECs) (Figure 40a). In a second step the capacity of dPGS to downregulate the growth 
factors-induced proliferation was investigated (Figure 40b).  
ka (M-1s-1) = (6.6±0.6) E+06 
kd (s-1) = (3.49±0.32) E-02 
KD = (5.3±0.01) E-09 







                c)  
Figure 40: Angiogenic growth factors induced HUVECs proliferation and inhibition via dPGS. a) Growth 
factors-dependent stimulation of HUVECs cells proliferation. HUVEC cells were incubated for 72 hours in 
EBM medium supplied with either FGF1, FGF2 or VEGF growth factor at concentrations ranging between 0,1 
ng/ml and 1 µg/ml. The proliferation was measured via CellTiter 96 AQueous One Solution. The values are 
reported as absorbance normalized to the untreated control. Points represent the mean n=3 experiments each 
performed in quadruplicate ± SD. b) Cell viability determination for HUVECs after treatment in EGM-2 
complete medium with dPGS at the reported concentrations for 72 hours. The cell viability was measured via 
CellTiter-Glo Luminescent Cell Viability Assay. Values are expressed in percentage of Relative Light Units 
(RLU) normalized to control untreated cells. Bars represent the mean n=2 experiments each performed in 
quadruplicate ± SD. c) dPGS-dependent inhibition of growth factors-supported HUVECs proliferation. Cells 
were treated for 72 hours in EBM medium supplied with either 50 ng/ml FGF1, 3 ng/ml FGF2 or 50 ng/ml 
VEGF and increasing concentrations of dPGS ranging between 5 to 50 µM. The values are expressed in 
percentage as absorbance at 490 nm normalized to the untreated control. Points represents the mean n=3 
experiments each performed in quadruplicate ± S.D. *P<0.05, **P<0,01, ***P<0,001 vs vehicle control. 
Statistics were determined using a one-way AVOVA followed by a Dunned ´s post-test (Graphpad Prism, 
version 5).  
The experiment reported in Figure 40a allowed to define the concentration of 
growth factors needed to stimulate HUVECs proliferation. Interestingly, the growth factor 
FGF2 highly supported HUVECs growth, with a 3.36-fold enhancement in comparison to 
control untreated cells, already at 10 ng/ml. The growth factor VEGF similarly induced a 
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dose-dependent proliferation increase but it reached a maximal stimulation within 10-100 
ng/ml with a 1.7-fold increase, before decreasing at higher concentration. FGF1 indeed 
showed a good proliferative capacity, still behind FGF2 in terms of fold-enhancement, 
however inducing a 2.6-fold increase at 100 ng/ml. The results enabled to determine the 
growth factors concentration to use for further proliferation inhibition experiments. 
Specifically, FGF2 was applied at 3 ng/ml concentration, whereas in the case of FGF1 and 
VEGF 50 ng/ml were further used.  
Nevertheless, before using dPGS for inhibition studies, it was necessary to verify 
the cytotoxicity profile of it for HUVECs. Therefore, a cell viability assay was carried out 
after 72 hours of incubation with increasing concentrations of dPGS (Figure 40b). 
The polysulfate did not cause significant cytotoxic effects and only a slight reduction of the 
viability was measured upon treatment with 50 µM (88% compared to control untreated set 
to 100%). Concentrations below did not result toxic and, by contrast, enhanced the 
proliferation up to 20% when compared to the control untreated. Accordingly, no 
substantial toxic effect of dPGS for the cell line used in the study was observed.  
Ultimately, using the concentrations of the growth factors above mentioned and a 
range of concentrations of dPGS between 5 and 50 µM, the capacity of dPGS to negatively 
regulate the proliferation of HUVECs stimulated by FGF1, FGF2 or VEGF was examined. 
The inhibition of the growth factor-induced proliferation is shown in Figure 40c. 
For all three growth factors tested dPGS induced a concentration-dependent reduction of 
the proliferation. Notably, in the case of FGF2-stimulated proliferation, a significant dPGS-
induced decrease of the proliferation was observed with a calculated IC50 of 21 µM. 
Nevertheless, given the binding evaluations for FGF1 and VEGF to dPGS (3.2.3) a less 
effective interaction could be assumed, which could consequentially affect the activity of 
the sulfated inhibitor. Considerably, for FGF1 only a hypothetical IC50>50 µM was 
calculated. Instead, for VEGF, even though dPGS induced a concentration-dependent 
reduction of the growth factor-induced proliferation, the reduced VEGF-dependent 
stimulation of the cell proliferation limited the use of dPGS concentrations above 12.5 µM.  
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Moreover, in the same experimental setting, the growth factors-inhibitory activity 
of dPGS was compared to heparin (Figure 41). The growth factors studied are known to 
bind to heparin, but the functionality of this binding results in positive and negative 
stimulation of the factors activity in a concentration-dependent manner. The results 
confirmed a concentration-dependent inhibitory capacity of heparin especially in the case 
of FGF2 and VEGF, whereas no effect was observed for FGF1. Notably, dPGS in 
comparison to heparin always resulted in a stronger downregulation of growth factor-
dependent HUVECs proliferation.  
Figure 41: Comparison of growth factor-dependent HUVECs proliferation via dPGS and heparin. dPGS 
and heparin-dependent inhibition of growth factors-supported endothelial cell proliferation. HUVEC cells were 
treated for 72 hours in EBM medium supplied with either 50 ng/ml FGF1, 3 ng/ml FGF2 or 50 ng/ml VEGF 
and increasing concentrations of either dPGS or heparin ranging between 5 to 50 µM. The values are expressed 
in percentage as absorbance at 490 nm normalized to the untreated control. Points represent the mean n=3 
experiments each performed in quadruplicate ± S.D.  
 dPGS-inhibition of HUVECs tubes-like structure formation   
In the context of evaluating the anti-angiogenic capacity of dPGS, the HUVECs 
tube formation assay was carried out (Figure 42). The assay bases on the capacity of 
HUVECs to differentiate, directionally migrate toward angiogenic stimuli, to align and 
branch forming three-dimensional capillary-like tubular structures, which mimic the 
polygonal networks of blood vessels. In the tube formation assay HUVECs adhered to a 
reduced growth factor basement membrane (with major protein components including 
laminin, collagen IV, entactin, and HSPG). For studying the inhibition of capillaries 
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formation via dPGS, HUVECs were seeded in EGM-2 medium containing dPGS at 
concentrations of 5, 10 and 50 µM. Initially, the tube formation was observed at three-time 
points (5, 8 and 20 hours) to estimate the timing for dPGS-endothelial tube inhibition 
(Figure 42). For easier comparisons, the assessment of total tube length per field of control 
untreated versus dPGS treatments is displayed. After 5 hours incubation dPGS induced a 
reduction of tube formation efficiency. Moreover, the effect of dPGS increased with the 
time resulting in a clear dose-dependent inhibition after 8- and 20-hours incubation. 
Especially, at 50 µM concentration dPGS induced 77% inhibition of tube-like structures 
formation already at 5 hours incubation, whereas after 8- and 20-hours incubation this 
concentration resulted in the complete absence of tubes.  and induced the cells toward 
cluster form.  
Additionally, the tube formation efficiency was assessed after 8 hours incubation 
via comparing three parameters: the number of nodes, total tubes length and total meshes 
area of dPGS treatments versus control untreated (Figure 43). A clear concentration-
dependent inhibition of capillary-like structures was observed upon dPGS treatment for all 
parameters analyzed. Generally, 5 µM dPGS caused a percentage decrease in tube 
formation capacity which ranges between 8-21%, whereas 10 µM resulted in a 38-44% 
reduction, in comparison to untreated control set to 100%. Important to notice that, 
considering the cytotoxicity assay in Figure 40a, a toxic effect of dPGS can be excluded. 
In fact, for the tube formation assay, for example, after 8 hours incubation, dPGS reached 
IC50 at ~ 30 µM (considering all three parameters), whereas at 50 µM only a 12% reduction 
of the viability was observed, additionally after 72 hours incubation.  





Figure 42: dPGS inhibits HUVECs-tube formation on Matrigel. Some representative images of HUVECs 
tube formation inhibition on a Matrigel by dPGS at 5, 10, and 50 μM after 5, 8- and 20-hours incubation. 
HUVEC cells were seeded in EGM-2 medium at the density of 1x104 cells per well in a µ-slide plate (Ibidi) 
and reported dPGS concentrations. The pictures were taken with inverted phase-contrast microscope Axio 
Observer z.1 at 4x magnification and analyzed via ImageJ macro Angiogenesis Analyser. Parameter displayed: 
total tube length per field in pixels. dPGS shows a dose-dependent inhibitory effect on tube formation. When 
complete absence of tube formation was observed and the numerical quantification could not be performed the 
value was set to 0 and reported in the graph as non-determined (n.d.). Bars represent the mean n=2 independent 
experiments each performed in triplicates ± S.D. *P<0.05, **P<0,01, *** P<0,001 vs untreated control. 
Statistical significance determined non-parametric Kruskal-Wallis test followed by Dunn´s post hoc test 
(Graphpad Prism 5.03).  






Figure 43: Quantification of dPGS- inhibition of HUVEC-tube formation after 8 hours incubation via 
three parameters analysis. Representative images of HUVECs tube formation inhibition on a Matrigel by 
dPGS at 5, 10, and 50 μM after 8 hours incubation. 4x magnification phase-contrast pictures were analyzed via 
ImageJ macro Angiogenesis Analyser. Parameter displayed: total number of nodes, tube length, meshes area 
per field (px). Bars represent the mean n=2 independent experiments each performed in triplicates ± S.D. 
*P<0.05, **P<0,01, *** P<0,001 vs untreated control. Statistical significance determined by non-parametric 
Kruskal-Wallis test followed by Dunn´s post hoc test (Graphpad Prism 5.03).  




4.1 General considerations regarding the aim of the study 
Cancer is a complex, multifactorial and heterogeneous disease derived from the 
accumulation of several adaptive genetic and epigenetic mutations, which alter multiple 
pathways to ultimately drive the neoplastic transformation [2,9]. Traditional therapies 
based on the use of cytotoxic agents, as chemotherapy, have a reduced cancer cell 
specificity, thereby causing diverse side effects in patients [270]. To circumvent this 
problem, outstanding progress has been made in the last decades to unravel the mechanisms 
governing tumorigenesis, leading to the design of compounds that specifically hit single 
tumor targets, the so-called “target drugs”, with reduced off-target side effects. 
Although targeted therapies still represent a great promise in the treatment of several cancer 
types, they suffer of considerable drawbacks that limit their therapeutic efficiency. 
The heterogenic nature of cancer but also to its adaptive capabilities refer to this problem. 
A single targeted therapy often results in development of therapeutic resistance with cancer 
relapse as consequence of genetic modifications of the target. Besides, limited efficiency 
due to multiple pathways redundancy, compensatory cross-talks and alternative pathways 
activation occur. An example is the acquired resistance in patients in response to the first 
FDA approved anti-angiogenic drug, the monoclonal antibody Bevacizumab against VEGF 
[218,271]. 
Thus, for the treatment of complex pathologies such as cancer, it appears more 
likely to achieve a higher therapeutic efficiency via modulating multiple targets rather than 
a single one, though at the expense of specificity [272]. In this context, multi-target drugs 
gained considerable interest during the last, and from being unattractive compounds 
became an emerging therapeutic alternative.  
The multi-target drug design is a challenging task with respect to off-target effects. 
In this context, HSPGs are a suitable blueprint for the development of multi-target drugs 
given to their affinity to a wide variety of proteins and enzymes by which they regulate 
pleiotropic physiological and pathophysiological functions. Interactions of HSPGs to 
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proteins mostly depend on electrostatic binding between HS and basic motifs located on 
the targets. In this context, the potential of the HS analogue heparin for the treatment of 
complex diseases as cancer, inflammation, and infection has been well documented [37–
41]. However, the anticoagulant capacity besides its animal origin are known limitations 
for a therapeutic application. Consequently, attentions have been addressed towards 
synthetic heparin mimetics with reduced heparin derived-side effects, besides retaining a 
high therapeutic efficacy.  
In this regard, the aim of this investigation was to evaluate the potential of a 
synthetic heparin mimetic, the dendritic polyglycerol sulfate (dPGS), with respect to 
modulating multiple tumorigenic pathways. In particular, among the long list of HS-
regulated cancer signals, this work focused on two relevant tumor-promoting mechanisms: 
the Shh-pathway and angiogenesis. Background of this work are extensive in vitro and in 
vivo validations of the anti-inflammatory and anti-complement capacity of dPGS 
[246,247,251,254,273], which support the more recent in vivo studies on the tumorigenic 
targeting abilities of dPGS, applied as a drug carrier [259,260]. Thus, in this study for the 
first time, the anti-tumorigenic capacities of dPGS in relation to other relevant cancer 
signaling mechanisms have been investigated.  
4.2 Shh-N protein expression and binding characterization to dendritic 
polyglycerol sulfates  
Initially, the human recombinant Shh protein was successfully expressed in 
eukaryotic cells (HEK293 cells). The mammalian expression system is a widely used 
system to enable the expression of Shh protein carrying the dual lipidation necessary for 
the protein activity [70,274]. Only the active part of the protein, the 19 kDa Shh-N terminal 
fragment, was expressed as recombinant fusion protein linked to a C-terminal His-tag for 
further purification. This construct, lacking the autocatalytic and cholesterol transferase 
enabling C-terminal domain, resulted in the variant also named Shh-Nu, carrying only the 
N-terminal palmitoylated modification, which shows reduced membrane anchoring 
capacity, and thus can be easily secreted in the medium [59]. Nevertheless, Shh-Nu is 
known for presenting unaltered binding affinity to the PTCH receptor and analogous 
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activity in comparison to the ShhNp (fully lipidated) in cell-based studies [58]. 
On the contrary, in developmental studies, the lack of the cholesterol motif impairs protein 
trafficking, thereby altering long-range signaling and maximal pathway activity [60,61,63].  
The presence of secreted ~19 kDa Shh-N in the conditioned medium derived from 
HEK293 cells transiently transfected was confirmed via Coomassie gel staining and 
immunodetection (Figure 12). Interestingly, for the expressed Shh-N three bands pattern 
could be detected. Several evidence report that for ShhNp (dually lipidated) two variants 
with a slightly differential migration pattern are secreted and correspond to the membrane-
tethered fraction (cholesterol-modified and palmitoylated) and a soluble one (due to lipids 
removal via Disp and sheddases) [70,79,275]. Having expressed the cholesterol-deficient 
Shh-Nu, it can be assumed that the predominant secreted variant corresponds to the soluble 
form lacking cholesterol but carrying palmitoylation, which is easily released in the 
medium given its reduced membrane tethering. Besides, the palmitoylated Shh variant can 
be either secreted as membrane-anchored protein, as for the unprocessed ShhNp, or as 
processed soluble form lacking both cholesterol and palmitoylation due to sheddases 
cleavage of the palmitoyl motif. Potential cellular material as plasma membrane fragments 
carrying Shh-N not removed by centrifugation might also correspond to one of the observed 
bands.  
As usual first step generally characterizing the here described experimental 
approach, the binding affinity between protein and sulfated compounds was assessed via 
SPR analysis. In the case of Shh-N, the expressed and purified protein was applied for SPR 
affinity measurements to dPGS and the degradable variant dPGTPS. Both variants carry 
the same core (dPG) and share an equal sulfation degree (~90%). In contrast to dPGS, 
dPGTPS contains a long, flexible and hydrophobic linker, which carries an ester 
functionality enabling hydrolytic and cellular enzymatic cleavage [256]. Moreover, the 
variant used in the present study contains azide groups, which enables further dye coupling 
for in vivo imaging. Despite the structural differences, the two variants showed the same 
binding behavior for Shh-N. KD values in the nanomolar range were achieved (Figure 14). 
Interestingly, Zhang et al. studied the affinity via SPR of mouse-derived Shh to heparin and 
its natural ligand HS [276]. The authors report a good binding affinity for heparin with a 
KD value of 67 nM and observed a weaker interaction toward HS (KD 32 µM), which 
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suggests a preferential binding for Shh to highly sulfated regions.  Research from Whalen 
and coworkers calculated an 800 nM KD affinity for murine Shh to heparin while a KD of 
14.5 µM was measured in case of HS binding [83]. In this context, the binding studies 
performed in the present work support as well an enhanced binding affinity to Shh for 
highly sulfated compounds, which is as well analogous to its interaction to heparin. 
The data from dendritic polyglycerol sulfates imply an effective competitive role in a 
physiological context regarding the weaker affinity for Shh to its natural ligand HS. 
4.3 Cell-based evaluation of dPGS/dPGTPS-dependent Shh pathway 
inhibition  
The nature of the previously confirmed affinity was further evaluated in more 
psychological context via measuring the Shh pathway activity in two reporter cell-based 
assays: the luciferase reporter (Figure 19) and alkaline phosphatase (ALP) expression 
assay (Figure 16). These two methods are widely used as indicators of pathway activity 
and efficiently applied for evaluating the activity of agonists/antagonists of Shh pathway in 
vitro [277,278]. Briefly, ALP assay is based on the capacity of Shh pathway to induce 
osteoblast differentiation in a mouse mesenchymal cell line, the C3H10T1/2. 
Exogenous Shh ligand binds to PTCH receptor, expressed by the mouse fibroblasts, and 
results in increased expression of cell differentiation biomarker ALP [279–281]. 
Regarding the luciferase report system, a mouse embryonic fibroblast NIH-3T3 cell line 
was stably co-transfected with a GLI-dependent firefly luciferase reporter plasmid 
containing eight GLI binding sites (8xGLI-BS) and renilla luciferase (pRL-TK) as internal 
control plasmid [126]. The stimulation of Shh pathway results in nuclear translocation of 
the transcription factor GLI and binding to the 8xGLI binding sites on the luciferase 
promoter, stimulating the enzyme expression.  
In both assays, the activation of the pathway was specifically obtained upon cell 
incubation with Shh CM. A control with a specific Shh-pathway inhibitor was included by 
using a small molecule that antagonizes the activity of GLI-transcription factors, 
GANT61 [143]. For both bioassays, the specific downstream pathway inhibitor GANT61 
showed comparable down-regulating activity with IC50 in µM range (IC50 of 8.8 µM for 
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ALP-assay and 1.2 µM for luciferase reporter activity). Notably, the results are in 
agreement with the expected activity for GANT61 found in the literature, which reports an 
IC50 of ≥5µM for both bioassays [282]. However, while for dPGTPS an equally strong 
inhibitory capacity was confirmed in both methods (IC50 of 72 and 111 nM for ALP and 
luciferase assay, respectively) a conflicting behavior was observed for dPGS and heparin. 
Treatment with dPGS resulted in an IC50 for the ALP-assay of 81 nM, which reflects a 
strong interference potential, whereas in the luciferase reporter system the IC50 increased 
80-fold (6.5 µM). Even more pronounced, heparin only showed a good inhibitory potential 
in the nM range in the ALP-assay whereas for the luciferase-based system no significative 
down-regulating activity was detected.  
To explain the different behavior of dPGS and dPGTPS in the luciferase-based 
assay, several cytotoxicity studies were performed, and they ruled out any cytotoxic effect 
contribution.  However, a possible limitation of the study, in the case of the luciferase-
reporter assay, was the lack of normalization to the internal control (renilla luciferase). 
Moreover, the reduced amount of FBS (2% for ALP production in C3H10T1/2 cells 
compared to 0.5% in the luciferase-expressing cell line ShhL2) might play a role. 
Nevertheless, the different architecture of both sulfated polymers seems to influence the 
outcome.   
Besides the Shh-pathway, bone morphogenic proteins (BMPs) and Wnt signals 
contribute to the osteoblast differentiation, via acting on the key regulatory element Runx2, 
essential for ALP expression [283,284]. Since it has been discovered that Shh ligand drives 
mesenchymal pre-osteoblasts cell differentiation and induces ALP expression, the 
synergism between Shh-pathway and BMPs signals found several confirmations. 
Although, Shh did not seem to directly affect the expression of relevant BMPs at the mRNA 
level [278,280,281]. Later, Zhao et al. confirmed a GLI-2-dependent upregulation of BMP-
2 at the mRNA level and GLI-2-mediated Shh-BMP-2 synergistic enhancement of ALP 
expression and osteoblast differentiation [285]. Similarly, for Wnt proteins, several 
evidence suggest that Shh-Wnt crosstalk is involved in regulating ALP expression in 
C3H10T1/2 cells, as confirmed by the reduction of both Shh- and BMP-2-induced ALP 
expression upon treatment with Wnt specific inhibitors [286,287]. Interestingly, both BMP-
2 and Wnt are known to bind with high affinity to heparin [288–291]. In this context, it 
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might be assumed that dPGS, dPGTPS, and heparin could act synergistically on other 
effectors that are up-regulated upon Shh-pathways activation, resulting in a decreased ALP 
expression. To the best of my knowledge, only Manikowski et al. studied the ability of 
soluble heparin and HS oligosaccharides to inhibit Shh-pathway activation, by inhibiting 
C3H10T1/2 cell differentiation [80]. If from one side my results find consistency in the 
findings of Manikowski, on the other hand, the divergence observed in the two bioassays,  
as in the case of heparin activity, suggests a potential shortcoming of the mentioned work 
concerning the lack of confirmation in alternative cell-based assays.  
Still, an unsolved question is why dPGTPS showed good inhibitory activity in the 
luciferase-based assay. Either the compound interferes directly with the luciferase activity 
or its distinct architecture enables a more efficient cellular uptake and intracellular 
distribution compared to dPGS. Regarding the ester functionalized linker of dPGTPS, 
which is prone to hydrolytic cleavage [256], it can be hypothesized that the effect observed 
for dPGTPS could be a consequence of intracellular degradation. Degradation in 
lysosomes, where the Shh-dPGTPS complex potentially accumulates after entry, could 
result in the release of polysulfated shell fragments containing the hydrophobic linker. 
After the lysosomal escape, these fragments might target intracellular GLI factors or be 
recycled and inserted into the plasma membrane where binding of additional exogenous 
Shh further contributes to pathway inhibition. However, this theory would require further 
investigations. 
4.4 Evaluation of the anti-proliferative capacity of dPGS and variant in 
2D cell culture-based assays 
It was investigated whether dPGS and dPGTPS, via binding to Shh-N, could 
interfere with pathway activation and consequentially limit cancer cell proliferation. 
Overexpression of key regulators of the Shh pathway, including the ligand itself has been 
demonstrated in the pancreatic ductal carcinoma cell lines PANC-1 and Mia-PaCa-2 
[292,293] and the breast carcinoma cell line MCF-7 [294,295], whereas in the non-small 
cell lung cancer cells line A549 lower amount of ligand compared to high GLI-factors 
expression is confirmed [296].  
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Whether the secreted ligand activates autocrine or paracrine Shh-pathway is 
somehow contradictory. For A549 cells, while Singh et al. report an autocrine pathway-
dependent cell proliferation [297], Bermudez et al. showed the absence of response to 
exogenous Shh ligand, thus supporting paracrine signaling [296]. For pancreatic cancer 
cells while paracrine signal finds more confirmations [119,123,124] yet Petrova et al. 
supported autocrine activation [147].   
Thus, in this study, for each cell-line, the secretion of Shh-N was firstly verified and 
quantified via ELISA-based assay (Figure 22). A remarkable Shh-N expression and release 
was confirmed in the case of PANC-1 and MCF-7 cells, besides a reduced level for A549 
cells, and around basal level for the control non-carcinogenic cell lines HEK293 (human 
embryonic kidney) and C3H10T1/2 (mouse fibroblasts).  
Subsequentially, autocrine-stimulated cancer cell was studied in the low-level Shh 
ligand producer A549 cell line (Figure 23) and the high-level ligand producer PANC-1 
(Figure 24). Cell line HEK293 (Figure 25) served as a control. Proliferation was quantified 
via endpoint measurements and in real-time. The consistency of the two methods was in 
agreement with already published evaluations [298]. Notably, dPGS had no influence on 
cell proliferation, not even at the highest concentration used (30 µM). In the context of Shh-
pathway, it might be expected that dPGS would potentially inhibit the autocrine pathway 
activation and as a result limit cell proliferation. Nevertheless, this scenario relies on the 
eventuality that these cells would preferably use autocrine instead of paracrine Shh-
signaling, a point that requires further studies.  
Contrary, dPGTPS induced a concentration-dependent reduction of cell 
proliferation, which also includes the non-tumorigenic control cell line HEK293. This again 
points to additional effects of this compound. 
4.5 Evaluation of anti-proliferative capacities of dPGS/dPGTPS in 3D 
spheroids model 
Significantly, 3D cell culture-based systems, as cellular spheroids, are known to 
resemble more in vivo situations as the 2D monolayer culture are able to. Spheroids, as 
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microscale cells clusters formed by self-assembly, develop above 400 µm diameter a 
necrotic hypoxic internal core, a middle quiescent and an external proliferating layer, which 
results upon oxygen and nutrients limitation besides waste and ECM accumulation (along 
a gradient from extern to intern), as observed in many solid tumors [299,300]. 
Furthermore, in contrast to 2D cell culture system, the cells within the spheroid  i) retain 
their genetic profile, original morphology and polarity, ii) show increased cell-cell 
adhesion, which regulates mechanotransduction and signaling in response to growth 
factors, iii) depone their own ECM with increasing cells-ECM contact, which in turn 
activates survival and proliferation pathways [301]. Generally, the increased cells adhesion 
and ECM density are limiting factors for drugs diffusion, and, along with hypoxia, are the 
causes of increasing therapeutic resistance observed in 3D in comparison to 2D monolayer 
culture, which moreover reflects the failure rate of drugs when applied in vivo studies [302]. 
Thus, 3D cell culture systems provide insights closer to in vivo situations not achievable by 
traditional 2D monolayer cell studies.   
Therefore, in this study, was analyzed the effects of polysulfates on spheroids that 
reached after 4 days of incubation a ~400 µm diameter. As a parameter for growth 
evaluation, the change in spheroids volume was quantified, as one of the common feature 
applied in tumoral spheroid characterization [265]. The monitoring was performed over 15 
days in case of low-rate growing A549 cells and, for faster-growing cells such as PANC-1 
and HEK293, up to 5-times increase of the initial volume (5xVday4), according to the 
protocol of Friedrich et al. [269]. Moreover, at 72 hours after treatment, viability tests were 
carried out, to exclude the eventuality of cytotoxic influences. Nevertheless, a more precise 
evaluation of the spheroids viability could be obtained by performing cytotoxicity analysis 
for each time point during the whole morphological observation, such as by real-time 
analysis.  
Contrary to the 2D cell-based assays, each of the cell lines studied responded to 
dPGS and dPGTPS treatment in a cell line-dependent manner. In case of A549 cells, dPGS 
at concentrations ≥30 nM caused ~91% volume reduction after 15 days incubation. 
Nevertheless, this effect is observable even after 2-day treatment (Figure 27). 
A surprising result considering the monolayer measurements. For PANC-1 cells, dPGS 
induced a clear dose-dependent growth reduction at the end of the observation (8 days of 
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treatment), though to a lower extent than A549 spheroids (Figure 30). Additionally, after 
72 hours of incubation, no significant toxic effect was observed for both cell lines. 
Given the strong anti-proliferative effect observed for A549 cellular spheroids the 
reasons for dPGS-dependent growth reduction, in this case, might rely on:  
1) Spheroid’s differential characteristics compared to the 2D cell culture system. 
Spheroids are i) able to depose their own ECM with increased secretion of 
collagen, fibronectin-1, and laminin [303–305], ii) show upregulated 
expression of integrins (cell-ECM contacts) and E-cadherins (cell-cell 
interaction) [306,307], iii) additionally, the increased hypoxia, derived from the 
3D cellular assembling, induces over-expression of HIF (hypoxia-induced 
factor), which is involved in upregulation of pro-angiogenic factors.  
2) binding of dPGS to a long list of ECM, proangiogenic factors, membrane and 
membrane-associated proteins, including β−integrins, transferrin receptor and 
collagen [250,308].  
3) the high rate of dPGS internalization, confirmed in the case of A549 cells 
[249,257,309], following possibly clathrin/caveolin-mediated endocytosis and 
energy independent mechanisms [308], which might positively contribute to 
enhancing the anti-proliferative effect.  
The same trend of response was also detected for PANC-1 cells, but clear significant 
growth retardation was only detected at 30 µM dPGS treatment.  
Thus, the results on the spheroids growth, especially for A549 cells, rather than 
referring to the capacity of dPGS to influence Shh-related proliferation, provides new 
insights on the anti-proliferative cell-dependent potential of dPGS, additionally in a context 
mimicking closely in vivo situations, whether the precise mechanism of action remains 
unclear.  
Interestingly, MacDonald et al. showed a growth reduction of pancreatic cancer 
spheroids treated with the heparin mimetic necuparanib (M402) [310]. 
The authors observed that the spheroids of pancreatic cancer cells reduced their diameter 
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and increased sphericity upon compound treatment. Similarly, in my investigation, both 
A549 and PANC-1 cells showed a reduction of the size of the spheroids upon treatment, 
rather than cell loss and disaggregation, as usually caused by toxic agents. 
Furthermore, MacDonald et al. via proteomic analysis of the supernatant from tumor-
stroma cells co-cultured spheroids identified several proteins involved in tumorigenic 
pathways, which undergo alteration upon treatment with necuranib. Similarly, an additional 
set of proteins expressed during tumor spheroids growth might explain the effect of dPGS. 
Notably, in a published poster, but not in the mentioned article, the authors report the 
necuparanib-induced reduction of proliferation also in 2D culture system, performed 
however over a time of seven days incubation [311]. This suggests one possible explanation 
for the inconsistency between the 2D and 3D proliferation assays observed in my study, 
which might also lie on the shorter length of the treatment in case of monolayer cell 
proliferation. 
Indeed, in the case of HEK293 cells, a diameter dependent change in the 
morphology of the cells was observed upon dPGS treatment at concentrations above 300 
nM. For the spheroids which reached ~400 µm diameter after 4 days of incubation and 
~600 µm after 3 days treatment (7 days of culture), dPGS treatment-induced evident loss 
of spheroid integrity at 3 µM and slight conformational changes at 30 µM, resulting in 
apparent volume increase upon treatment. Reducing the initial number of cells and enabling 
the formation of ~300 µm diameter by day 4th of incubation, led to spheroid formation at 
day 7of ~500 µm diameter, unaffected by dPGS treatment both in morphology and growth 
rate. Additionally, at this time point, no cytotoxic effect was observed. However, a later 
observation of the same spheroids, when they reached diameter ~800 µm, revealed again 
the same trend of structural alteration. Importantly, for the control spheroids, no 
conformational changes were detected during the whole incubation time. 
Given the diameter-dependent effect, it could be assumed that factors, such as the 
formation of the necrotic core and hypoxia increase, which generally takes place ≥400 µm 
diameter, could play an important role in explaining the effect of dPGS on the morphology 
of HEK293 cells. A further explanation could be the increase of stress on the spheroids 
surface, due to the rapid HEK293 cells proliferation, which would result in increased 
sensitivity to dPGS. In fact, spheroids are known to undergo morphological changes during 
long-term growth, potentially losing the structural integrity as events that not necessary 
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corresponds to increased toxicity [312,313]. Given the rapid proliferation characterizing 
the HEK293 cells, it might be possible to rapidly reach unstable conditions within the 3D 
structure, resulting in unpredictable morphological changes. Thus, while HEK293 is very 
robust and a stable cell line in 2D monolayer, it might not be very suitable for 3D systems.  
Spheroids treatment with dPGTPS resulted in reduced activity when compared to 
dPGS. Furthermore, dPGTPS treatment of cells monolayer and spheroids substantially 
differ in cytotoxicity: in the monolayer, a concentration-dependent proliferation reduction 
effect could be observed, whereas in the spheroids the treatment caused only a slight 
increase of the toxicity, additionally cells-specific. The increase of spheroids resistance in 
comparison to monolayer is well described [314,315].  
It can be concluded that the results obtained for dPGS and dPGTPS regarding their 
influence on tumorigenic and non-tumorigenic cell spheroid growth provide preliminary 
insights concerning the anti-proliferative activity in 3D culture. Further investigations are 
necessary to clarify the initial observations.  
4.6 dPGS as a potential inhibitor of heparanase and angiogenesis  
In the context of developing anti-angiogenic compounds, given the complex 
mechanisms interplay and pathways redundancy involved within the angiogenic cascade, 
multi-target strategies might be of therapeutic advantage. As several angiogenic factors 
depend on the interaction with HS in order to elicit their signals, heparin shows increased 
anti-angiogenic capacities while regulating synergistically multiple factors along the 
angiogenic signaling, targeting of proangiogenic growth factors (such as FGFs, HBEGF, 
and VEGF) and additionally blocking the endoglucoronidase heparanase. 
As previously mentioned, several heparin mimetics with low-anticoagulant 
capacities have been synthetized in order to overcome the therapeutic limitations related to 
heparin, while retaining high heparanase inhibitory capacity and moreover high affinity to 
the pro-angiogenic growth factors. In this context, it was investigated whether dPGS, 
interacts with both heparanase and the relevant pro-angiogenic growth factors. To note that 
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the studies concerning angiogenesis have solely been performed with dPGS, which might 
be the starting point to expand future investigations. 
SPR binding studies showed a high affinity for dPGS to heparanase with KD value 
of 3.1 nM, additionally characterized by a slow dissociation rate, which indicates stable 
binding (Figure 36). Furthermore, the pro-angiogenic growth factors present a good 
binding affinity to dPGS with KD values in low nM range (Figure 39), in particular: 170 
nM for FGF1, 5.9 nM for VEGF, and 25 nM for FGF2. The KD values reported in literature 
for heparin-binding to FGF1 range between 5 to 180 nM [316,317], for FGF2 between 7.9 
and 23 nM [167,318] and for VEGF from 157 to 165 nM [317]. The range of results is 
attributed to different experimental methodologies. Interestingly, Siska et al. performed 
SPR studies via using a SA-sensor chip and measured a KD value for heparin-binding to 
FGF1 of 4.2 nM, FGF2 of 5.3 nM and VEGF of 42 nM [320]. In comparison to heparin, 
dPGS showed a 40-fold and 4.7-fold lower binding affinity to FGF1 and FGF2, 
respectively, while the binding to VEGF is enhanced of 4.7-fold. However, when compared 
to PI-88, a famous anti-angiogenic heparin mimetic (chapter 1.4.5), dPGS showed an 
increased affinity regarding FGF2 binding (KD=95 nM for PI-88) and a comparable affinity 
to VEGF (KD=2 nM for PI-88). In contrast PI-88 showed a 850-fold higher affinity to FGF1 
(KD=200 pM) in comparison to dPGS [235]. 
As the binding studies give important preliminary information, further studies in a 
more physiological context, are essential to better understand the relevance of the 
interactions. With this aim in view, in vitro non-cell based assays were carried out to 
evaluate the capacity of dPGS to inhibit the activity of human heparanase, while cell-based 
in vitro studies were performed to validate the down-regulation dPGS-dependent of 
angiogenic processes elicited by the proangiogenic growth factors. 
To assess heparanase activity, the method described by Hammond et al. and based 
on the cleavage of the synthetic heparin oligosaccharide fondaparinux [268] was applied. 
In the assay, the capacity of dPGS to act as heparanase inhibitor was compared with its 
analogue heparin and the commercial heparanase inhibitor Suramin. Suramin is a 
polysulfonated naphthylurea-based small molecule able to inhibit heparanase with an IC50 
of 46 µM [321], but with reduced therapeutic applicability due to high toxicity [197]. The 
results in Figure 38b confirmed that the strong binding affinity earlier measured (KD=3.1 
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nM) mirrors a strong enzymatic inhibitory capacity for dPGS, with an IC50 of 2 nM. 
Likewise, heparin showed an equally strong inhibitory capacity as dPGS, with matching 
IC50 value, confirming overall the extreme potential of heparin to inhibit heparanase, in 
agreement previous studies [322,323], and relevantly in accordance with the IC50 measured 
by Loka et al. [324]. Moreover, a 4000-times higher IC50 was measured for Suramin, 
confirming its modest inhibitory potential, in agreement with previous studies [321]. 
Interestingly, the comparison of dPGS to anti-angiogenic compounds already introduced in 
clinical trials as PI-88 (IC50 of 8 nM) and its derivative PG545 (IC50 of 6 nM) [235], dPGS 
has competitive performance. Furthermore, dPGS might possibly compete with one of the 
most potent heparanase inhibitor, the non-anticoagulant N-acetylated glycol-split heparin 
roneparstat (SST0001) with reported IC50 of 3 nM [233]. Future cell-based in vitro assays 
and in vivo models are necessary for further evaluations with respect to the high relevance 
of heparanase in diverse pathological settings. 
The anti-angiogenic potential of dPGS was further evaluated by its ability to 
downregulate pro-angiogenic growth factors induced-HUVECs proliferation. 
Therefore, the initial growth factors dose-dependent enhancement of the HUVECs 
proliferation was confirmed, which allowed defining the concentrations required to reach 
maximal stimulation (Figure 40a). Interestingly in the case of VEGF, a maximum of a 1.7-
fold increase was measured in comparison to the untreated control at 10-100 ng/ml, while 
a concentration above resulted in a signal reduction. By contrast, maximal stimulation with 
3.4-fold enhancement was observed in case of treatment with 10 ng/ml of FGF2, whereas 
FGF1 resulted in a 2.6-fold enhancement at 100 ng/ml concentration. This differential 
capacity of the FGFs compared to VEGF to induce ECs proliferation, especially in the case 
of HUVECs, is consistent with previous findings.  Bompais et al. observed in HUVECs a 
1.6-fold maximal enhancement for VEGF at 8 ng/ml while 2 ng/ml of FGF2 induced a 2.7-
increase [325]. Similarly was reported a ~1.3 increased activity of FGFs in comparison to 
VEGF [326–328]. In agreement with the inter-dependency of differential growth factors to 
synergistically promote the angiogenic response, the combination of the angiogenic factors 
would stimulate the proliferation of HUVECs to a greater extent than a single cytokine 
[326].  
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By inducing HUVECs growth factors-dependent proliferation with either 3 ng/ml 
FGF2 or 50 ng/ml of VEGF and FGF1, the anti-angiogenic capacity of dPGS was further 
studied. As shown in Figure 40c, dPGS reduced in a dose-dependent manner HUVECs 
proliferation stimulated by the growth factors. As expected from the binding studies, a 
stronger inhibition was observed in the case of FGF2 with a calculated IC50 of 21 µM. For 
VEGF a clear inhibition could be detected with a 40% reduction upon treatment with 12.5 
µM dPGS. The proliferation of FGF1 was also reduced by dPGS but to a lower extent (IC50 
>50 µM). It is of note that the dPGS within this range of concentrations did not induce 
toxicity as confirmed by the viability test performed at 72 hours after incubation (Figure 
40b). Compound PI-88 shows in the same experimental setting IC50 values ranging between 
40 µM, in case of FGF1-stimulation, to 10 and 20 µM, in case of FGF2 and VEGF-
stimulation respectively [329]. Of note, in the mentioned work the initial stimulation values 
are not reported. Moreover, dPGS induced stronger inhibition in comparison to UFH 
(Figure 41). Heparin showed a slight dose-dependent reduction of FGF2 and VEGF-
induced ECs proliferation, which reflects the anti-angiogenic feature of heparin at high 
concentrations, while a pro-angiogenic character is expected at lower concentrations [169].  
To evaluate further the angiogenic potential of dPGS in vitro, the reduction of three-
dimensional capillary-like tubular structures formation by HUVECs on a growth factor-
reduced basement membrane matrix was assessed. In this experimental setting, the capacity 
of HUVECs to adhere and form branches on the matrix depends upon the stimulation of 
the ECs with complete growth medium that contains several growth factors such as FGF2, 
VEGF, insulin-like growth factor (IGF-1) and epidermal growth factors (EGF). 
Although dPGS is able already after 5 hours to reduce the formation of tubes like-
structures, longer incubation time resulted in a clear dose-dependent inhibition. 
After 8 hours of incubation, dPGS decreased tube formation to 50% at a concentration of 
around 30 µM (Figure 41). The result might reflect the synergistic inhibition of FGF2 and 
VEGF. Nevertheless, inhibition due to the binding of dPGS to the low content of laminin 
or collagen that constitutes the matrix cannot be excluded. Notably, PI-88 inhibits at 18 
hours HUVECs tube-formation of 29% at 10 µM concentration [329], whereas dPGS 
already reached around 40% reduction after 8 hours incubation. In this term, dPGS might 
be able to compete in terms of efficiency with other anti-angiogenic heparin mimetics 
relying on both on heparanase and angiogenic growth factors inhibition. Furthermore, it is 
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of interest that a hydrophobic moiety, as in the case of the PI-88 derivative PG-545 
enhances the anti-angiogenic potential [235]. Thus, testing of the dPGS derivative dPGTPS, 
which contains a hydrophobic linker, could hypothetically result in an increased protein 
affinity and stronger anti-angiogenic potential. 
4.7 Concluding remarks and future perspective 
The aim of this work was to evaluate the anti-tumorigenic potential of dendritic 
polyglycerol sulfates, besides their well-known anti-inflammatory and anticomplement 
capacities. In the context of inhibiting HSPG-regulated tumorigenic processes, the capacity 
of dendritic polyglycerol sulfates to interfere with the sonic hedgehog signaling pathway 
and the process of angiogenesis was evaluated. SPR-based assays confirmed affine binding 
of the two synthetic polysulfates, dPGS and the degradable derivative dPGTPS to the Shh-
N protein, heparanase, and pro-angiogenic growth factors (VEGF, FGF1, and FGF2).  
Protein binding per se could result in either positive or negative regulation of 
physiological pathways. Therefore, further activity studies are necessary to unravel whether 
binding inhibits or supports protein function. Concerning the Shh-pathway, the polysulfates 
demonstrated good inhibitory capacity in the low nanomolar range in an alkaline 
phosphatase reporter cell line. In a second approach, activation of the sonic hedgehog 
pathway was evaluated via a luciferase-reporter cell-based assay. While the compound 
dPGTPS showed again effective inhibition, the IC50 of dPGS tremendously increased to 6 
µM, but still, a dose-dependent inhibition was detectable. Besides shielding of the Shh 
protein secondary effects seem to mediate better inhibition in the case of dPGTPS.  
The anti-proliferative capacities of the sulfated compounds were studied in two 
cancer cell lines, PANC-1 and A549, which secrete the Shh-ligand and are known to be 
dependent on the Shh-pathway for cell proliferation. In this regard 2D and 3D cell culture-
based systems were applied. While dPGS did not show to significantly influence the cell 
growth in 2D monolayer assays, dPGTPS caused a concentration dependent reduction of 
the cell proliferation, significantly in the case of A549 cells. Interestingly, in the 3D 
spheroid-based system, dPGS and dPGTPS significantly reduced A549 cell growth and, to 
a lesser extent, also PANC-1 cell growth. The results might reflect the different properties 
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the cells adopt to grow within the multilayer spheroid architecture in contrast to monolayer 
culture. These first data highlight the relevance of the 3D culture system that closer reflects 
tumorigenesis under in vivo conditions. Future studies concerning the anti-tumorigenic 
capacities of polysulfates should intensify research in this area.  
Concerning angiogenesis, dPGS demonstrated a high potential as a heparanase 
inhibitor, with an IC50 in the low nanomolar range. In this regard, it would be extremely 
interesting to further expand this study by applying dPGS in heparanase-driven endothelial 
cell sprouting and ECM degradation in metastatic processes, i.e.,  reduction of invasiveness 
and tumorigenesis of highly metastatic cell lines known to express a high level of 
endogenous heparanase. Further, dPGS also inhibited angiogenic growth factors activities, 
probably by competitive binding and shielding receptor recognition. Moreover, via acting 
on multiple targets simultaneously, dPGS potentially leads to an amplified anti-angiogenic 
response. Further in vitro studies should evaluate the reduction of EC migration and 
invasion likewise in vivo models might support more substantially the anti-angiogenic 
potential of dPGS.  
Thus, in the context of multitarget drug development for tumor therapy, multivalent 
polysulfates such as dPGS and dPGTPS demonstrate promising features to target intrinsic 
cancer-associated pathways.  




In the context of drug development for the treatment of complex diseases such as 
cancer, it might be necessary to interfere with multiple targets. Inspired by the multiple 
functions of heparan sulfate proteoglycans (HSPGs) several compounds have been 
developed in the past. Here the fully synthetic dendritic polyglycerol sulfates dPGS and 
dPGTPS were evaluated with respect to their overall anti-tumorigenic properties. 
Primarily focused on the sonic hedgehog (Shh) pathway, which is upregulated in several 
aggressive tumors, it was found that both compounds reduce pathway activation. 
Shh binding was analyzed via SPR and gave the following KD values: 88.7 nM for dPGS 
and 37 nM for dPGTPS. The inhibition of the Shh-signaling pathway was further evaluated 
in two reporter cell-based systems: a luciferase reporter and an alkaline phosphatase (ALP) 
assay. While dPGTPS showed consistently strong pathway inhibitory activity (IC50 of 72 
nM in the ALP and 111 nM in the luciferase assay), dPGS displayed a different behavior 
(IC50 of 81 nM in ALP and 6.5 µM in luciferase assay), which might be attributed to the 
different architecture of the polysulfates. Cancer cell line proliferation also mediated by the 
Shh pathway was further analyzed in 2D cultures and 3D spheroid-based assays. 
In monolayer 2D studies, dPGS did not show any influence, while dPGTPS at µM 
concentrations reduced cell proliferation. By contrast, in 3D spheroid-based cultures, both 
dPGS and dPGTPS, significantly arrested the growth of A549 spheroids, although the latter 
compound to a lower extent.   
At the molecular level growth factors mediate cell proliferation. Therefore, binding 
of FGF1, FGF2, and VEGF165 to the polysulfates was analyzed, again via SPR. 
All proteins bound tightly to the sulfated compounds (i.e., KD of 25 nM for FGF2-dPGS 
interaction). Further, the capacity of dPGS to hamper angiogenic processes was confirmed 
in case of inhibition of HUVECs proliferation. FGF2-induced HUVECs proliferation was 
reduced upon dPGS treatment (IC50=21 µM) and cell differentiation to initiate three-
dimensional capillary-like tube formation dose-dependently blocked.  
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Heparanase is an essential enzyme to initiate remodeling of the extracellular matrix (ECM) 
during tumorigenesis.  The polysulfate dPGS displayed a remarkable affinity to the protein 
(KD of 3.11 nM) and blocked its enzymatic activity (IC50 = 2 nM).  
To conclude, these findings emphasize the potential of synthetic polysulfates and 
should inspire future studies to explore their anti-tumorigenic efficacy.  
 




Für die Entwicklung von Medikamenten die zur Behandlung komplexer 
Krankheiten eingesetzt werden sollen, kann es hilfreich sein multiple Zielstrukturen zu 
adressieren. Inspiriert durch die zahlreichen Funktionen der Heparansulfat-Proteoglykane 
(HSPG) wurden in der Vergangenheit zahlreiche Verbindungen synthetisiert. In dieser 
Arbeit wurden die vollsynthetisch hergestellten dendritischen Polyglycerinsulfate dPGS 
und dPGTPS hinsichtlich ihrer antitumorgenen Wirkung untersucht. Zunächst fokussiert 
auf den Sonic Hedgehog (Shh)-Signalweg, der in vielen agressiven Tumoren reaktiviert 
wird, konnte gezeigt werden, dass beide Verbindungen die Aktivität vermindern. Bindung 
des Proteins Shh wurde mittels Oberflächenplasmonresonanz Spektroskopie untersucht 
und ergab KD Werte von 88,7 nM für dPGS und 37 nM für dPGTPS. Die Inhibition des 
Shh-Signalweges wurde weiterhin in zwei zellbasierten Systemen evaluiert: einem 
Luciferase Reportertest und einem Alkalischer Phosphatase (ALP) Reportertest. Während 
dPGTPS übereinstimmend eine ausgeprägte Hemmung in beiden Reportersystemen zeigte 
(IC50 von 72 nM im ALP Test und 111 nM im Luciferase-basierten Test), ergab der Einsatz 
von dPGS ein anderes Bild (IC50 von 81 nM in ALP Test und 6.5 µM in Luciferase-
basierten Test), was möglicherweise auf die unterschiedliche Architektur der beiden 
Polysulfate zurückzuführen ist.  
Da die Proliferation von Krebszelllinien ebenfalls durch den Shh-Signalweg 
vermittelt werden kann, wurde dies in 2D-Zellkulturen und im 3D-Spheroid Modell 
untersucht. In Monolagen wachsender 2D Zellkultur zeigte dPGS keinen Einfluss, während 
dPGTPS in µM Konzentration eine Reduktion der Zellproliferation ergab. Ein anderes 
Verhalten ergab sich im 3D-Spheroid Modell. Hier zeigte sich, dass sowohl dPGS als auch 
dPGTPS signifikant das Wachstum von A549 Spheroiden verzögerte, wobei dPGTPS sich 
als weniger effektiv erwies. 
Auf molekularer Ebene vermitteln Wachstumsfaktoren die Zellproliferation. Daher 
wurde die Bindung von FGF1, FGF2 und VEGF165 an die Polysulfate mittels 
Oberflächenplasmonresonanz Spektroskopie untersucht. Hierbei zeigten alle Proteine eine 
hochaffine Bindung an die sulfatierten Verbindungen (z. B. KD von 25 nM für die FGF2-
dPGS Bindung). Weiterhin wurde die Fähigkeit von dPGS die Angiogenese zu beeinflussen 
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durch Hemmung der Proliferation am Beispiel von HUVECs bestätigt. FGF2-induzierte 
Proliferation von HUVECs wurde durch dPGS gehemmt (IC50=21 µM) und 
Zelldifferenzierung, hin zu einem dreidimensionalem kapillar-ähnlichen Netzwerk, 
blockiert.  
  Heparanase ist ein essentielles Enzym, das Remodelierungsprozesse der 
extrazellulären Matrix (ECM) in der Tumorgenese einleitet. Das Polysulfat dPGS zeigte 
eine bemerkenswerte Bindungsaffinität an das Protein (KD von 3.11 nM) und blockierte 
dessen enzymatische Aktivität (IC50=2 nM).  
Zusammenfassend weisen die Befunde auf das hohe Potential der synthetischen 
Polysulfate hin, die in weitere Studien zur Wirksamkeit ihrer antitumorgenen 
Eigenschaften untersucht werden sollte. 
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